These guidelines are intended for use by health care providers responsible for the management of immunocompetent infants and children aged 3 months to 18 years with uncomplicated community-acquired pneumonia in both ambulatory and hospital settings.
MESSAGE

Worldwide, the pediatric community-acquired pneumonia (PCAP) remains to be one of the most important pediatric infectious diseases. The magnitude of its impact gravely affects not only the health of the community but also the social and economic milieu of the society. This therefore warrants healthcare prioritization and focus. The Philippine Academy of Pediatric Pulmonologists joins the nation in addressing this medical concern thru this 2021 Clinical Practice Guidelines in the Evaluation and Management of Pediatric Community-Acquired Pneumonia. Since the last published guidelines in 2012 and 2016, several evidence-based breakthroughs have already emerged, and this latest guideline aims to update and standardize the pediatric care in the Philippines thru well-researched diagnostic and management strategies that will provide any health practitioner in the practice of pediatric medicine more ease and confidence in dealing with this particular childhood disease.

This 2021 PCAP CPG was born out of laborious perseverance and tremendous amount of time to finally be crafted and published. My warmest congratulations to the PAPP Task Force on pCAP, which is ably headed by Dr. Vina Jalandoni-Cabahug, together with Dr. Rose Capeding of the Pediatric Infectious Disease Society of the Philippines (PIDSP), who hurdled the odds and challenges and came up with an outstandingly well-crafted manuscript. Congratulations to all the members of the Task Force on PCAP and thank you to all the contributors and stakeholders as well. I also express my deep appreciation to the Philippine Pediatric Society for graciously supporting this worthwhile project. May this modest contribution create a significant impact on the pediatric health care in the Philippines.

This is indeed another feather on the cap of PAPP!

NEPHTHALIE R. ORDOÑEZ, M.D., MHA, FPPS, FPAPP
President
Philippine Academy of Pediatric Pulmonologists, Inc.
MESSAGE

Pneumonia remains to be one of the most common reasons for hospitalization in children adding to the family’s economic burden. Although there has been a large reduction in child mortality due to lower respiratory infections for the past 5 years, pneumonia still accounts for 14% of all deaths of children under 5 years. Nonetheless, children can be saved from dying from pneumonia. There are simple interventions to prevent it and effective low-cost medications to control and treat the infection.

The creation of clinical practice guidelines has truly been a valuable tool to medical practitioners to assist them in their overall care of their patients, ensuring that optimal health is restored. This updated Clinical Practice Guidelines in the Evaluation and Management of Pediatric Community-Acquired Pneumonia is indeed an additional knowledge to clinicians in their armamentarium in the care of children with pneumonia. New recommendations for each clinical question included in the guidelines have been soundly based on pooled well-reviewed scientific evidence.

On behalf of the Pediatric Infectious Disease Society of the Philippines (PIDSP), I would like to extend my deep gratitude to the Philippine Academy of Pediatric Pulmonologists (PAPP) for reaching out to our society to be partners in this worthwhile endeavor. This close collaboration between PAPP and PIDSP has certainly been fruitful and productive.

MARY ANN C. BUNYI, M.D., FPPS, FPIDSP
President
Pediatric Infectious disease Society of the Philippines, Inc.
MESSAGE

The development of an updated guideline in pediatric community acquired pneumonia has been one of our most awaited projects. We acknowledge the concerted and collaborative efforts of our pCAP task force members from PAPP and PIDSP spearheaded by Dr. Vina Jalandoni - Cabahug and Dr. Rose Capeding. Just like our previous editions, it has been a rigorous process of putting together and coming up with evidence-based answers to common clinical questions in the evaluation and management of pediatric community-acquired pneumonia. In line with our mission, and to help curb the burden of pneumonia, we aim for its widest dissemination and utilization among clinical practitioners, policy-makers and institutions involved in the care of Filipino children.

REGINA M. CANONIZADO, M.D., FPPS, FPAPP
Immediate Past President (2019-2021)
Philippine Academy of Pediatric Pulmonologists, Inc.
PAPP pCAP Adviser
MESSAGE

Greetings!

Pneumonia remains to be one of the leading causes of under-five deaths globally, with the disease burden affecting developing countries including the Philippines. Due to this fact, the Philippine Academy of Pediatric Pulmonologists, Inc., in partnership with the Pediatric Infectious Diseases Society of the Philippines, Inc., put together a taskforce to update the clinical practice guidelines for the evaluation and clinical management of pediatric community-acquired pneumonia in an official publication.

Despite the inherent limitations imposed by the COVID-19 pandemic, as the 2021 PCAP CPG update was being conceptualized, the Task Force was fully committed to fulfill its mandate to explore new development and evidences that will fill the gaps in knowledge on PCAP.

The 4th PCAP clinical practice guidelines in the evaluation and management of pediatric community acquired pneumonia (2021 PCAP CPG), an update from the 2016 installation, is focused on the recognition of community-acquired pneumonia, identification of appropriate and practical diagnostic procedures, and initiation of effective treatment and preventive measures among immunocompetent patients aged 3 months to 18 years.

PAPP and PIDSP would like to acknowledge the support of the Philippine Pediatric Society through its president, Dr. Jocelyn A. Eusebio, as well as the valuable participation of our key stakeholders involved in the clinical management of PCAP in reviewing this document. Most of their constructive comments and recommendations were addressed, while the rest will be considered in the preparation of the next CPG update in 2024 and in the development of future practice guidelines.

In fulfillment of the Task Force’s objective, in line with the mission statements of PAPP and PIDSP, this manuscript will be disseminated to physicians engaged in the care of Filipino children suffering from community-acquired pneumonia. This document is intended to guide general practitioners, pediatricians and specialists in the management of patients with PCAP, but should not supersede sound clinical judgement of the attending physician.

Thank you.

Sincerely,

MA. VICTORIA JALANDONI-CABAHUG, M.D., FPPS, FPAPP
Co-Chair, 2021 PCAP CPG Task Force

MARIA ROSARIO Z. CAPELING, M.D., FPPS, FPIDSP
Co-chair, 2021 PCAP CPG Task Force
PAPP BOARD 2021-2023

PRESIDENT: NEPTHALIE R. ORDONEZ, M.D.
VICE PRESIDENT: ANNA MARIE CONCEPCION S. PUTULIN, M.D.
SECRETARY: AMELIA G. CUNANAN, M.D.
TREASURER: ARNEIL T. SURATOS, M.D.
MEMBERS: BIBIANO D'B. REYES JR., M.D.
          EMILY G. RESURRECCION, M.D.
          MA. VICTORIA J. CABAHUG, M.D.
IMMEDIATE PAST PRESIDENT: REGINA M. CANONIZADO, M.D.

PIDSP BOARD 2020-2022

PRESIDENT: MARY ANN C. BUNYI, M.D.
VICE PRESIDENT: FATIMA I. GIMENEZ, M.D.
SECRETARY: JO-ANNE A. DE CASTRO, M.D.
ASSISTANT SECRETARY: MA. CARMEN B. NIEVERRA, M.D.
          JAY RON O. PADUA, M.D.
TREASURER: NANCY N. BERMAL, M.D.
ASSISTANT TREASURER: MARY ANTONETTE C. MADRID, M.D.
AUDITOR: CYNTHIA A. AGUIRRE, M.D.
IMMEDIATE PAST PRESIDENT: ANNA LISA T. ONG-LIM, M.D.
BOARD OF TRUSTEES: CYNTHIA A. AGUIRRE, M.D.
          GYNETH LOURDES G. BIBERA, M.D.
          MARIA ROSARIO Z. CAPEPING, M.D.
          MARIA ESTRELLA B. LITAM, M.D.
          MELBA V. MASIGAN, M.D.
2021 PAPP/PIDSP JOINT TASK FORCE ON PCAP

OVER-ALL CHAIR: MA. VICTORIA S. JALANDONI-CABAHUG, M.D.

CO-CHAIR: MARIA ROSARIO Z. CAPEDING, M.D.

STEERING COMMITTEE:

KRISTINE ALVARADO-DELA CRUZ, M.D.
MARK JOSEPH S. CASTELLANO, M.D.
MARIA NERISSA A. DE LEON, M.D.
JAY RON O. PADUA, M.D.
MA. THERESA T. POLICARPIO, M.D.
MA. DULCE E. REQUIRON-SY, M.D.

TECHNICAL WORKING GROUP:

MAYLENE M. AGRIMANO M.D.
KRISTINE T. ALILING, M.D.
ANGELYN A. CORONEL, M.D.
LESLEY ANNE C. DELA CRUZ, M.D.
CHARITO C. DE LOS SANTOS, M.D.
CYNTHIA CECILIA J. DE OCAMPO, M.D.
MARIA CECILIA C. GALANG, M.D.
KAREN NICOLE C. LLAMAS, M.D.
GRACE V. MALAYAN, M.D.
RODALIZA R. MANGLICMOT-GUMBOC, M.D.
RAYMUND ANTHONY L. MANUEL, M.D.
CATHERINE S. PALAYPAYON, M.D.
FRANCESCA MAE T. PANTIG, M.D.
BEATRIZ PRAXEDES APOLLA MANDANAS-PAZ, M.D.
MARIA ANGELA NICOLE S. PERRERAS, M.D.
SUZANNE S. PONIO-DEGOLLADO, M.D.
CARINA DE TORRES-PURCELL, M.D.
MARMON O. SANCHEZ, M.D.
JEROME V. SENEN, M.D.
MELODY K. TOLENTINO, M.D.
MA. KRISTINA U. TORIO, M.D.

MR. RAYMARK SALONGA
MR. GUILLIANO LACSAMANA

ADVISER & HONORARY MEMBER: CRISTAN Q. CABANILLA, M.D.
PAPP TASKFORCE ON PCAP ADVISER: REGINA M. CANONIZADO, M.D.
Table of Contents

PREFACE 9
Lead CPG Developers 10
Scope, Objectives, and Target Users of the Clinical Practice Guidelines 10
Clinical questions pertaining to evaluation, treatment and prevention 11
Literature search, and inclusion and appraisal of evidence 12
Quality Assessment using GRADE Approach 13
Reporting of results of studies in the Summary of Evidence 13
Grade recommendation with description of level of evidence 14
Stakeholder’s consultation 14
Formulation of the final draft 15
Dissemination and Monitoring Plan 16

Clinical Question 1 17
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS, WHAT CLINICAL SIGNS AND SYMPTOMS WILL ACCURATELY DIAGNOSE COMMUNITY-ACQUIRED PNEUMONIA? 17

Clinical Question 2 21
AMONG INFANTS AND CHILDREN 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT CLINICAL AND ANCILLARY PARAMETERS WILL DETERMINE THE NEED FOR ADMISSION? 21

Clinical Question 3 26
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS, WHAT DIAGNOSTIC AIDS WILL CONFIRM THE PRESENCE OF NON-SEVERE COMMUNITY-ACQUIRED PNEUMONIA IN AN AMBULATORY SETTING? 26

Clinical Question 4 27
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS, WHAT DIAGNOSTIC AIDS WILL CONFIRM THE PRESENCE OF SEVERE COMMUNITY-ACQUIRED PNEUMONIA IN A HOSPITAL SETTING? 27

Clinical Question 5 31
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT CLINICAL AND ANCILLARY PARAMETERS WILL DETERMINE THE NEED FOR ANTIBIOTIC TREATMENT? 31
Clinical Question 6A
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT EMPIRIC TREATMENT IS EFFECTIVE IF A BACTERIAL ETIOLOGY IS CONSIDERED? 35

Clinical Question 6B
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH BACTERIAL COMMUNITY-ACQUIRED PNEUMONIA, WILL THE ADDITION OF A MACROLIDE TO STANDARD EMPIRIC REGIMEN IMPROVE TREATMENT OUTCOME? 42

Clinical Question 7
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT TREATMENT IS EFFECTIVE IF A VIRAL ETIOLOGY IS CONSIDERED? 45

Clinical Question 8
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT CLINICAL AND ANCILLARY PARAMETERS WILL DETERMINE A GOOD RESPONSE TO CURRENT THERAPEUTIC MANAGEMENT? 48

Clinical Question 9
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT CAN BE DONE IF THE PATIENT IS NOT RESPONDING TO CURRENT THERAPEUTIC MANAGEMENT? 51

Clinical Question 10
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS, WHAT CLINICAL PARAMETERS WILL DETERMINE THAT SWITCH THERAPY CAN BE CONSIDERED IN THE MANAGEMENT OF SEVERE COMMUNITY-ACQUIRED PNEUMONIA? 54

Clinical Question 11
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS, WHAT ADJUNCTIVE TREATMENT IS EFFECTIVE FOR COMMUNITY-ACQUIRED PNEUMONIA? 58

Clinical Question 12
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 3 YEARS, WHAT INTERVENTIONS ARE EFFECTIVE FOR THE PREVENTION OF COMMUNITY-ACQUIRED PNEUMONIA? 62

APPENDICES
Appendix A. Imaging modalities for Pediatric Community-Acquired Pneumonia 70
Appendix B. 2016 PCAP CPG Key Recommendations (attach the actual soft copy of the 2016 CPG as some items are missing here) 71
PREFACE

The Clinical Practice Guidelines (CPG) for the Diagnosis and Management of Pediatric Community-Acquired Pneumonia (PCAP) was initiated by the Philippine Academy of Pediatric Pulmonologists, Inc. (PAPP) and the Pediatric Infectious Disease Society of the Philippines (PIDSP), in cooperation with Philippine Pediatric Society, Inc. (PPS) way back in 2004. Several CPG updates were then undertaken by the PAPP PCAP CPG Task Force from 2008 to 2016. Clinically-relevant research questions were answered with recent and current recommendations based on evidence from local and international data.

The 2021 PCAP CPG initiative was envisioned in March 2018 upon the recommendations of the 2018 PAPP Board for the purpose of updating the evidence in the PCAP CPG 2016 clinical questions. This led to the collaboration of PAPP and PIDSP to develop this CPG. Individual members were identified from each society as content experts to form the Steering Committee along with a clinical epidemiologist and technical writer as review experts. The committee identified the scope and target end user of the CPG as well as additional clinical questions to be included in the 2021 update aside from the questions on the previous CPGs. Selected members from the two societies formed the Technical Working Group (TWG) who did the literature search, appraisal of evidences, and formulation of recommendations. These recommendations were then presented to the stakeholders who became part of the consensus panel. There was no identified conflict of interest among the CPG developers, TWG members and stakeholders. A survey to determine potential competing interests were conducted during the development of this CPG. This initiative was fully funded by the PAPP and PIDSP societies.

The 2021 PCAP CPG significantly differs from the previous CPGs in several aspects. First, the current guideline is a consensus between two pediatric societies. Second, much of the literature review has been centered on meta-analyses or systematic reviews instead of individual studies. Finally, appraisal of published literature was based on Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria. Such methodological differences may provide difficulties in defining evolution of care through the years.

As identified in the previous CPG updates, there is lack of local data hence most of the evidences gathered came from international studies. The applicability of such data to the local setting needs to be critically assessed for its value and relevance. Corollary to this, several gaps in knowledge are identified and these may serve as a guide for future research.
Lead CPG Developers

The lead CPG developer is formed by key members from the Philippine Academy of Pediatric Pulmonologists and the Pediatric Infectious Disease Society of the Philippines. Together with two evidence review experts, they identified the scope and the target end user of the CPG, coordinated meetings during the development of the CPG, and relevant stakeholders who will be part of the consensus panel.

A Technical Working Group composed of PAPP and PIDSP members is likewise formed to conduct literature search, appraisal of evidence, and formulation of recommendations. This organized PCAP CPG team is identified as the 2021 PAPP/PIDSP Joint Task Force on PCAP in this manuscript.

Scope, Objectives, and Target Users of the Clinical Practice Guidelines

The 2021 Clinical Practice Guidelines in the Evaluation and Management of Pediatric Community- Acquired Pneumonia (2021 PCAP CPG) is focused on the recognition of clinical features, appropriate and practical diagnostic procedures, effective therapeutic management and preventive measures in an immunocompetent infant and children aged 3 months to 18 years with uncomplicated community-acquired pneumonia. This does not cover topics on coronavirus disease 2019 (COVID-19) pneumonia as well as recurrent, persistent, complicated, aspiration, and health care-associated pneumonia. Moreover, differentiating the three broad categories namely bacterial, viral and atypical pathogens in terms of their peculiar management approaches were not tackled. Treatment options were directed to the most common causative agents for PCAP but are not organism-specific and did not include pathogens such as Mycobacterium tuberculosis, fungi, and viruses other than the Influenza virus. These guidelines are intended for use by health care providers responsible for the management of PCAP in both ambulatory and hospital settings. This CPG is envisioned to guide the clinician and should not supersede sound clinical judgement in the overall care of pediatric patients with community-acquired pneumonia.
Clinical questions pertaining to evaluation, treatment and prevention

The lead CPG developers updated the recommendations to answer the clinical questions formulated in the first Clinical Practice Guideline in the Evaluation and Management of Pediatric Community-acquired Pneumonia (2004) created by the joint efforts of PPS, PIDSP, and PAPP. The clinical questions in 2004 were identified through consensus meetings among the lead CPG developers then and were based on a prospective study on the knowledge, attitude, and practice of pediatricians, family physicians, and general practitioners in the Philippines. The 2008, 2012 and 2016 CPG updates used the same clinical questions.

The following clinical questions were addressed in this 2021 PCAP CPG:

1. Among infants and children aged 3 months to 18 years (P), what clinical signs and symptoms (E) will accurately diagnose community-acquired pneumonia (O)?

2. Among infants and children 3 months and 18 years with community-acquired pneumonia (P), what clinical and ancillary parameters (E) will determine the need for admission (O)?

3. Among infants and children aged 3 months to 18 years (P), what diagnostic aids (I) will confirm the presence of non-severe community-acquired pneumonia (O) in an ambulatory setting?

4. Among infants and children aged 3 months to 18 years (P), what diagnostic aids (E) will confirm the presence of severe community-acquired pneumonia (O) in a hospital setting?

5. Among infants and children aged 3 months to 18 years with community-acquired pneumonia (P), what clinical and ancillary parameters (E) will determine the need for antibiotic treatment (O)?

6. This is divided into 6A which is the original clinical question from the previous CPGs and 6B to address the question on the benefit of adding a macrolide in the empiric treatment of bacterial PCAP.
   6.1 Among infants and children aged 3 months to 18 years with community-acquired pneumonia (P), what empiric treatment (I) is effective if a bacterial etiology is considered?*
   6.2 Among infants and children aged 3 months to 18 years with bacterial community-acquired pneumonia (P), will the addition of a macrolide (I) to standard empiric regimen (C) improve treatment outcome (O)?*

7. Among infants and children aged 3 months to 18 years with community-acquired pneumonia (P), what treatment (I) is effective if a viral etiology is considered?*

8. Among infants and children aged 3 months to 18 years with community-acquired pneumonia (P), what clinical and ancillary parameters (E) will determine a good response (O) to current therapeutic management?
9. Among infants and children aged 3 months to 18 years, with community-acquired pneumonia (P), what can be done (I) if the patient is not responding to current therapeutic management?

10. Among infants and children aged 3 months to 18 years (P), what clinical parameters (E) will determine that switch therapy (O) can be considered in the management of severe community-acquired pneumonia?

11. Among infants and children aged 3 months to 18 years (P), what adjunctive treatment (I) is effective for community-acquired pneumonia?

12. Among infants and children aged 3 months to 18 years (P), what interventions (I) are effective for the prevention of community-acquired pneumonia (O)?

*Outcomes of interest include severity, risk for mortality, length of hospital stay, and duration of illness*

Literature search, and inclusion and appraisal of evidence

The literature search, and inclusion and appraisal of evidence was made in line with DOH and PhilHealth’s Manual for Clinical Practice Guideline Development (2018). Members of the TWG assigned in each clinical question were tasked to search the literature. Local researches submitted to the Philippine Pediatric Society (PPS) and published on the Abstracts of Philippine Pediatric Researches 2012-2015, Philippine Academy of Pediatric Pulmonologists (PAPP), and Pediatric Infectious Disease Society of the Philippines (PIDSP) Journal, Health Research and Development Information Network (HERDIN); and international publications identified using the systematic literature search of PubMed, Cochrane Library, and Google Scholar databases were searched and limited to the following: [1] Existing CPGs, meta-analyses or systematic reviews (individual studies were considered in the absence of the aforementioned study types); [2] source of data from January 1, 2016 to April 31, 2021; [3] 3 months to 18 years of age; and [4] immunocompetent host. Search terms were structured based on the PICO format of each clinical question. Bibliography search within the initially selected articles was also done to expand literature search.

Based on the Manual for Clinical Practice Guideline Development 2018, existing and published CPGs, systematic reviews and meta-analyses can be used as references to answer the PICO questions. In this case, an existing systematic review is evaluated to determine if it can be used instead of performing a de novo systematic review. Titles and abstracts were screened and those that met the inclusion criteria for each clinical question were retrieved as full-text.
Quality Assessment using GRADE Approach

<table>
<thead>
<tr>
<th>STUDY DESIGN</th>
<th>QUALITY OF EVIDENCE</th>
<th>DOWNGRADE IN PRESENCE OF</th>
<th>UPGRADE IN PRESENCE OF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized trial</td>
<td>High</td>
<td>Risk of bias (−1) Serious (−2) Very serious</td>
<td>Large effect (+1) Large, no plausible confounders, consistent and direct evidence</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>Inconsistency (−1) Serious (−2) Very serious</td>
<td>(+2) Very large, no major threats to validity and direct evidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Indirectness (−1) Serious (−2) Very serious</td>
<td>Dose response (+1) Evidence of a gradient</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Imprecision (−1) Serious (−2) Very serious</td>
<td>All plausible confounding (+1) Would reduce a demonstrated effect</td>
</tr>
<tr>
<td>Observational study</td>
<td>Low</td>
<td>Publication bias (−1) Serious (−2) Very serious</td>
<td>(+1) Would suggest a spurious effect when results show no effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Very low</td>
<td></td>
</tr>
</tbody>
</table>


Appraisal of evidence and interpretation of results were done in line with DOH and PhilHealth guidelines. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach was used in assessing the quality of evidence and strength of recommendations. GRADE was developed by an international panel that considered clinical questions on diagnosis, screening, prevention and therapy, and assessing them based on potential sources of bias.

For existing Clinical Practice Guidelines, the International Appraisal of Guidelines, Research and Evaluation version 2009 (AGREE II) was used. This is also an internationally-recognized assessment tool endorsed by DOH. This tool consists of the following dimensions: Scope and Purpose, Stakeholder Involvement, Rigor of Development, Clarity of Presentation, Applicability, Editorial Independence, and Overall Guideline Assessment.

Reporting of results of studies in the Summary of Evidence

The results of studies as reported in the Summary of Evidence are summarized to include study design, clinically important end points, and effect measures.
Grade recommendation with description of level of evidence

The 2021 PCAP CPG adopted the following recommendation statement as supported by corresponding levels of evidence:

<table>
<thead>
<tr>
<th>GRADE</th>
<th>Strength of recommendation</th>
<th>Recommendation Statement</th>
<th>Description of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Strong</td>
<td>Should [or should not] be recommended OR Strongly [or strongly not] recommended</td>
<td>Evidence based on an existing high-quality CPG, meta-analysis, or systematic review.</td>
</tr>
<tr>
<td>Moderate</td>
<td>Can be strong or conditional</td>
<td>Is [or is not] recommended</td>
<td>Evidence based on an existing moderate quality CPG, meta-analysis, systematic review, or individual studies with definite evidence.</td>
</tr>
<tr>
<td>Low or Very Low</td>
<td>Conditional</td>
<td>Is [or is not] suggested/considered</td>
<td>Evidence based on an existing low-quality CPG, meta-analysis, systematic review, or individual studies with equivocal evidence.</td>
</tr>
<tr>
<td>No evidence</td>
<td>Conditional</td>
<td>Expert opinion</td>
<td>The recommendation was based on a consensus among members of the 2021 PAPP/PCAP Joint Task Force on PCAP.</td>
</tr>
</tbody>
</table>

Development of recommendations also accounted for facilitators and barriers to implementation. These include the presence or lack of training and/or access to resources to follow the recommendation. A limitation, however, in the development of recommendations is the lack of economic evaluation of the health interventions mentioned and so the costs of interventions as potential barrier were not presented.

Stakeholder’s consultation

Results of questionnaire surveys on PCAP among participants of the PAPP Annual Convention from 2016-2019 were reviewed and considered in this 2021 CPG. In addition, a preliminary draft was sent to selected stakeholders for individual evaluation as to clarity, acceptability, and applicability of the CPG. The preliminary draft was also presented to them by the lead CPG developers through an online teleconference where each stakeholder was given the opportunity to ask clarifications and give comments. Potential facilitators and barriers for the CPG pursued were brought up during the stakeholder’s consultation and these were considered when the finalizing the CPG. Opinions expressed by the individual stakeholder did not necessarily reflect the medical society or institution he/she is affiliated with.
The following stakeholders were engaged during the development of this CPG:

1. CLEMENCIA BONDOC M.D. - Association of Municipal Health Officers of the Philippines (AMHOP)
2. ZASHKA ALEXIS GOMEZ, M.D. - DOH - Disease Prevention and Control Bureau (DOH-DPCB)
3. RAZEL NIKKA HAO, M.D. - DOH - Disease Prevention and Control Bureau (DOH-DPCB)
4. JAN DEREK JUNIO, M.D. - DOH - Disease Prevention and Control Bureau (DOH-DPCB)
5. MR. PHILIP BUGAYONG - DOH - National Reference Laboratories (DOH-RITM-NRL) for Microbiology and Virology
6. MAYAN LUMANDAS, M.D. - DOH - National Reference Laboratories (DOH-RITM-NRL) for Microbiology and Virology
7. FERDINAND DE GUZMAN, M.D. - Philippine Academy of Family Physicians (PAFP)
8. RACQUEL LOPEZ, M.D. - Philippine Academy of Family Physicians (PAFP)
9. ENDRIK SY, M.D. - Philippine Academy of Family Physicians (PAFP)
10. DORIS LOUISE OBRA, M.D. - Philippine Academy of Pediatric Pulmonologists (PAPP)
11. RITA MARIE LOURDES VERGARA, M.D. - Philippine Academy of Pediatric Pulmonologists (PAPP)
12. RODOLFO PAGCATIPUNAN, JR., M.D. - Philippine College of Chest Physicians (PCCP)
13. RICHARD HENRY SANTOS, M.D. - Philippine College of Emergency Medicine
14. PATRICK JOSEPH TIGLAO, M.D. - Philippine College of Emergency Medicine
15. MS. CHARISSE BANAAG - Philippine Health Insurance Corporation (PhilHealth)
16. MERCY JEANE UY-ARAGON, M.D. - Pediatric Infectious Disease Society of the Philippines (PIDSP)
17. BELLE RANILE, M.D. - Pediatric Infectious Disease Society of the Philippines (PIDSP)
18. MARGARITA LUISA ALFONSO, M.D. - Philippine Pediatric Society (PPS)
19. EDNA SARAH MORADA, M.D. - Philippine Pediatric Society (PPS)
20. MICHELLE ANNE MANGUBAT, M.D. - Philippine Society of Adolescent Medicine Specialists (PSAMS)
21. OLIVIA CAMILLE REYES, M.D. - Philippine Society of Pediatric Emergency Medicine
22. MA. VICTORIA RIBAYA, MD. - Philippine Society of Pediatric Emergency Medicine
23. ROBERTO PADUA, JR. M.D. - Philippine Society of Pathologists (PSP)
24. MIRIAN VITERBO, M.D. - Philippine Society of Pathologists (PSP)
25. NATHAN DAVID CONCEPCION, M.D. - Philippine Society of Pediatric Radiology
26. JOANNA CHOA-GO, M.D. - Philippine Society of Pediatric Radiology
27. LEONILA DANS, M.D. - Professor, University of the Philippines, Manila

Formulation of the final draft

At least three-fourths of the members of the PAPP and PIDSP lead CPG developers met through teleconferencing and voted to reach consensus for each recommendation. Consensus was defined as more than 75% of the participating members. Stakeholders made up the consensus panel during the finalization of the recommendations and consensus was defined as at least 75% agreement among the members (one organization is equivalent to one participation). As a contingent plan if a consensus is not reached in a clinical question, the members who disagree can present new evidence or perspectives to the lead CPG developers and concur again in a consensus panel meeting through teleconference. A survey will then be done to determine if a consensus can be made. If still a consensus regarding a clinical question is not attained despite the discussions, it will then be declared as undecided. However, for this CPG there was a consensus from the participating members in all the recommendations presented. The final draft was presented to the 2020-2021 PAPP and PIDSP Board Members for approval and official endorsement then forwarded to the stakeholders.
Dissemination and Monitoring Plan

Copies of the 2021 PCAP CPG will be distributed to PAPP, PIDSP, and PPS training institutions, posted on their official websites, and stakeholders’ websites. Survey forms will be disseminated during the annual conventions of the PAPP and PIDSP to assess compliance and applicability of the formulated guidelines. This will be done annually for the next 3 years in time for the next CPG update in 2024. Assessing the knowledge, attitude, and practices of physicians on the 2021 PCAP CPG will also be part of the research agenda of PAPP and PIDSP for the succeeding years.
Clinical Question 1
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS, WHAT CLINICAL SIGNS AND SYMPTOMS WILL ACCURATELY DIAGNOSE COMMUNITY-ACQUIRED PNEUMONIA?

KRISTINE T. ALILING, M.D.
CARINA DE TORRES - PURCELL, M.D.
MARIA CECILIA C. GALANG, M.D.

KEY RECOMMENDATION

Pediatric community-acquired pneumonia (PCAP) is considered in a patient who presents with cough or fever, PLUS any of the following positive predictors of radiographically-confirmed pneumonia¹: (Conditional recommendation, very low-grade evidence)

1. Tachypnea²
   1.1 3 months to 12 months old: ≥50 breaths per minute
   1.2 >1 year old to 5 years old: ≥40 breaths per minute
   1.3 >5 years to 12 years old: ≥30 breaths per minute
   1.4 >12 years old: ≥20 breaths per minute
2. Retractions or chest indrawing³
3. Nasal flaring
4. O₂ saturation <95% at room air⁴
5. Grunting

¹ Chest radiograph was the reference standard used in the studies.
² The age-specific definition of tachypnea was adopted from the WHO (below 5 years old) and PALS (age 5 years and above). Currently, there is no age-specific criteria of tachypnea in the Filipino population
³ Chest indrawing was defined by the WHO as “the inward movement of the lower chest wall when the child breathes in, and is a sign of respiratory distress. It does not refer to the inward movement of the soft tissue between the ribs.”
⁴ The oxygen saturation of <95% cut-off was based on expert opinion. No study was found that recommends a specific cut-off value predictive of pneumonia.
## SUMMARY OF EVIDENCE

<table>
<thead>
<tr>
<th>Outcome 1</th>
<th>Sensitivity, Specificity, +LR, -LR of clinical signs and symptoms in diagnosis of CAP in children</th>
<th>Importance: Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>17 (Schot, 2018)</td>
<td>Systematic Review</td>
<td>High prevalence pneumonia (&gt;10%)&lt;br&gt;Cough: Sen = 78.5-88&lt;br&gt;Sp = 16-30.2&lt;br&gt;PPV = 36.8-37.2.&lt;br&gt;NPV = 70.6-72.7.&lt;br&gt;LR = 1.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fever:&lt;br&gt;Sen = 47-94.&lt;br&gt;Sp = 36-68&lt;br&gt;PPV = 20-45.&lt;br&gt;NPV = 70-97.&lt;br&gt;LR = 2.9</td>
</tr>
<tr>
<td>23 (Shah 2017)</td>
<td>Meta-analysis of Cohort studies</td>
<td>Cough:&lt;br&gt;Sen = 88 (80-97)&lt;br&gt;+LR= 1.2 (0.98-1.4)&lt;br&gt;-LR= 0.47 (0.24-0.70)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fever: &gt;37.5 °C&lt;br&gt;Sen = 80-92&lt;br&gt;+LR= 1.7-1.8&lt;br&gt;-LR= 0.17-0.37</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chest pain:&lt;br&gt;Sen = 22 (5-62)&lt;br&gt;+LR= 1.9 (1.1-3.4)&lt;br&gt;-LR= 0.82 (0.66-1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oxygen saturation ≤96%:&lt;br&gt;Sen = 64 (49-78)&lt;br&gt;+LR= 2.8 (2.1-3.6)&lt;br&gt;-LR= 0.47 (0.32-0.67)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≤95%:&lt;br&gt;Sen = 16 (11-2)&lt;br&gt;+LR= 3.5 (2.0-6.4)&lt;br&gt;-LR= 0.88 (0.82-0.94)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≤92%:&lt;br&gt;Sen = 26 (21-32)&lt;br&gt;+LR= 2.2 (1.3-3.8)&lt;br&gt;-LR= 0.84 (0.76-0.94)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Grunting:&lt;br&gt;Sen = 13 (5-32)&lt;br&gt;+LR= 2.7 (1.5-5.1)&lt;br&gt;-LR= 0.92 (0.80-0.97)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nasal flaring:&lt;br&gt;Sen = 36 (17-54)&lt;br&gt;+LR= 2.2 (1.3-3.1)&lt;br&gt;-LR= 0.77 (0.64-0.90)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Retractions or indrawing:&lt;br&gt;Sen = 38 (20-56)&lt;br&gt;+LR= 1.9 (1.2-2.5)&lt;br&gt;-LR= 0.78 (0.61-0.94)</td>
</tr>
</tbody>
</table>
Meta-analysis of Cohort and Case-control studies

<table>
<thead>
<tr>
<th>Condition</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Positive LR</th>
<th>Negative LR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cough</td>
<td>Sen=96 (91-98)</td>
<td>Sp=14 (3-46)</td>
<td>+LR=1.12 (0.90-1.39)</td>
<td>-LR=0.30 (0.09-0.96)</td>
</tr>
<tr>
<td>History of fever</td>
<td>Sen=94 (88-97)</td>
<td>Sp=12 (6-23)</td>
<td>+LR=1.06 (1.0-1.12)</td>
<td>-LR=0.53 (0.41-0.69)</td>
</tr>
<tr>
<td>Respiratory rate ≥50</td>
<td>Sen=53 (30-74)</td>
<td>Sp=72 (58-83)</td>
<td>+LR=1.9 (1.5-2.5)</td>
<td>-LR=0.6 (0.5-0.9)</td>
</tr>
<tr>
<td>Nasal flaring</td>
<td>Sen=47 (28-66)</td>
<td>Sp=73 (52-87)</td>
<td>+LR=1.75 (1.20-2.56)</td>
<td>-LR=0.73 (0.59-0.89)</td>
</tr>
<tr>
<td>Grunting</td>
<td>Sen=24 (10-47)</td>
<td>Sp=87 (65-96)</td>
<td>+LR=1.8 (1.1-2.9)</td>
<td>-LR=0.9 (0.8-1.0)</td>
</tr>
<tr>
<td>Retractions or indrawing</td>
<td>Sen=48 (16-82)</td>
<td>Sp=72 (47-89)</td>
<td>+LR=1.8 (0.9-1.2)</td>
<td>-LR=0.7 (0.4-1.4)</td>
</tr>
</tbody>
</table>

**CONTEXT AND CONSIDERATIONS**

The positive predictors of radiographically-confirmed pneumonia were included based on the positive likelihood ratio of ≥2 or sensitivity of ≥80%. If the given criteria are not met but pneumonia is highly considered, further diagnostic work-up is suggested. Auscultatory lung findings such as decreased breath sounds, crackles or rales, wheeze and rhonchi were not included due to their low sensitivity (<80%) or positive likelihood ratio (<2) for diagnosing pneumonia mainly due to interobserver variability. No single clinical feature was found to predict pneumonia accurately. There was no supporting evidence on the predictive accuracy of a combination of signs and/or symptoms in giving a definitive diagnosis of pneumonia.

The 2021 PAPP/PIDSP Joint Task Force on PCAP retained the position statement of the 2012 PAPP 2nd PCAP update that chest radiograph is the reference standard in establishing the presence or absence of pneumonia. The task force similarly acknowledges the limitation of chest radiograph as a diagnostic tool. There is no evidence evaluating the accuracy in comparison with microbiology as the gold standard. In addition, moderate reliability exists due to interobserver variability in radiographic interpretation.

Even in the absence of chest radiograph, pneumonia may be considered using the above clinical predictors. Chest radiograph findings should always be correlated with the patient’s clinical findings. A normal chest radiograph does not exclude the presence of pneumonia. Inconsistencies in the chest radiograph and clinical findings warrant re-evaluation or referral to a specialist.
REFERENCES


Clinical Question 2
AMONG INFANTS AND CHILDREN 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT CLINICAL AND ANCILLARY PARAMETERS WILL DETERMINE THE NEED FOR ADMISSION?

MA. DULCE E. REQUIRON-SY, M.D.
CHARITO C. DE LOS SANTOS, M.D.

KEY RECOMMENDATION

Patients classified as having severe PCAP or high-risk for pneumonia-related mortality based on the following clinical parameters and/or ancillary features are considered for admission: (Conditional Recommendation, moderate to low-grade evidence)

<table>
<thead>
<tr>
<th>PARAMETERS AT SITE-OF-CARE</th>
<th>RISK CLASSIFICATION FOR PNEUMONIA-RELATED MORTALITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low Risk (Non-Severe PCAP)</td>
</tr>
<tr>
<td>Formerly classified as:</td>
<td>PCAP A</td>
</tr>
<tr>
<td>Clinical Parameters*</td>
<td></td>
</tr>
<tr>
<td>1. Respiratory signs</td>
<td></td>
</tr>
<tr>
<td>1.1 Cyanosis/ Hypoxemia</td>
<td>none</td>
</tr>
<tr>
<td>1.2 Head bobbing</td>
<td>none</td>
</tr>
<tr>
<td>1.3 Chest indrawing/Retractions</td>
<td>none</td>
</tr>
<tr>
<td>1.4 Apnea</td>
<td>none</td>
</tr>
<tr>
<td>1.5 Grunting</td>
<td>none</td>
</tr>
<tr>
<td>2. Central nervous system signs</td>
<td></td>
</tr>
<tr>
<td>2.1 Altered sensorium</td>
<td>none or irritable but consolable</td>
</tr>
<tr>
<td>2.2 Convulsion</td>
<td>none</td>
</tr>
<tr>
<td>3. Circulatory signs</td>
<td></td>
</tr>
<tr>
<td>3.1 Poor perfusion</td>
<td>none</td>
</tr>
<tr>
<td>3.2 Pallor</td>
<td>none</td>
</tr>
<tr>
<td>4. General considerations</td>
<td></td>
</tr>
<tr>
<td>4.1 Malnutrition**</td>
<td>none or mild</td>
</tr>
<tr>
<td>4.2 Refusal OR inability to drink/ feed/ take oral medications</td>
<td>no</td>
</tr>
<tr>
<td>4.3 Dehydration</td>
<td>none</td>
</tr>
<tr>
<td>4.4 Age &lt;6 months</td>
<td>no</td>
</tr>
</tbody>
</table>
Ancillary Parameters
(desirable variables but not necessary as determinants for admission at site-of-care)

<table>
<thead>
<tr>
<th>Ancillary Parameter</th>
<th>None</th>
<th>Present</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Chest radiograph or ultrasound findings of consolidation, multifocal disease, moderate to large effusion, abscess, air leak</td>
<td>none</td>
<td>present</td>
</tr>
<tr>
<td>6. Sustained oxygen saturation at RA using pulse oximetry for 20-30 minutes</td>
<td>≥94%</td>
<td>≤93%***</td>
</tr>
</tbody>
</table>

*Each of the clinical parameters and radiographic findings is an independent predictor of pneumonia-related mortality. The presence of any of the above predictors classifies the patient into the high-risk category.

**Weight for Height [WFH]:** moderate = SD score < -2; severe = SD score < -3 (WHO Management of severe malnutrition: a manual for physicians and other health workers. Geneva. World Health Organization 1999); Weight for Age (based on 2017 WHO IMCI Update on Assessing and managing children at primary healthcare facilities to prevent overweight and obesity in the context of the double burden of malnutrition): moderate = -2 SD (> -2 Z score); severe = -3 SD (> -3 Z score)

***If oxygen saturation is less than 90%, oxygen therapy should be initiated.

### SUMMARY OF EVIDENCE

<table>
<thead>
<tr>
<th>Outcome 1</th>
<th>Severe Pneumonia and Pneumonia-related Mortality</th>
<th>Importance: Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong># of studies included in MA or SR (and list of authors)</strong></td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>56 (Dean &amp; Florin, 2018)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
<td>Sustained ( \text{SpO}_2 ) of &lt; 90% at RA - hypoxemia OR = 11; 95% CI = 6.2 - 19.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age &lt;6 months associated with treatment failure and mortality OR = 2.2; 95% CI = 1.1 - 4.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chest indrawing was associated with severe outcomes OR = 2.12; 95% CI = 1.62 - 2.78</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Head bobbing was associated with mortality RR = 8.3; 95% CI = 2.71 - 12.77 and mechanical ventilation RR = 4.7 95% CI = 1.50 - 6.36</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Grunting is associated with hypoxemia and suggestive of impending respiratory failure OR = 5.210; 95% CI = 2.287 - 7.482</td>
</tr>
</tbody>
</table>

*Although body mass index (BMI) was not mentioned in the studies/reviews used in the development of this CPG, it may be used in the assessment of the nutritional status of children and adolescents. However, the same recommendations for malnutrition status as a parameter for admission cannot be applied since no evidence was gathered as to the level associated with mortality among patients with pneumonia.*
<table>
<thead>
<tr>
<th>Deardorff et al., 2018</th>
<th>Systematic review of cohort and case-control studies</th>
</tr>
</thead>
</table>

AMS associated with severe outcomes
OR = 11.9; 95% CI = 6.41 - 22.23

AMS - Glasgow Coma Score <13 was the most associated with mortality in children admitted with pneumonia
OR = 324; 95% CI = 131 - 805

In children admitted with WHO-defined severe or very severe pneumonia, AMS was associated with mortality
RR = 5.44; 95% CI = 1.34 - 17.56

In children admitted with WHO-defined pneumonia in a developing nation, “alteration of general status” based on clinician impression was also associated with mortality
OR = 3.23; 95% CI = 1.17 - 8.94

Oxygen saturation <90% at RA
OR = 20.9; 95% CI = 5.0 - 87

Chest indrawing
OR = 4.6; 95% CI = 2.2 - 9.4

Wheezing
OR = 0.2; 95% CI = 0.05 - 0.6

Refusing to feed
OR = 1.8; 95% CI = 0.9 - 3.8

Unable to drink/ breastfeed
OR = 1.8; 95% CI = 1.2 - 2.8

Weight for age:
Low (< -2 Zscore) OR = 2.5; 95% CI = 1.6 - 3.8
Very low (< -3 Zscore) OR = 6; 95% CI = 2.5 - 14.4

Weight for age:
Low (< -2 Zscore) OR = 2.1; 95% CI = 1.3 - 3.2
Very low (< -3 Zscore) OR = 3.8; 95% CI = 2.7 - 5.4

Dehydration
OR = 1.9; 95% CI = 1.3 - 2.8

Child not conscious at exam (mRISC)
OR = 2.3; 95% CI = 1.6 - 3.4

Moderate
**CONTEXT AND CONSIDERATIONS**

The PCAP Guideline development from 2004 through 2016 has been utilizing PCAP A, B, C, and D for its pneumonia risk classification nomenclature. The 2021 CPG lead developers recommend the use of Non-Severe PCAP or Low-Risk for pneumonia-related mortality in lieu of PCAP A and B and Severe PCAP or High Risk for pneumonia-related mortality in lieu of PCAP C and D. This change was done to align with existing international guidelines in classifying PCAP.

The Risk Classification for pneumonia-related mortality should be used when assessing a pediatric patient diagnosed to have community-acquired pneumonia for admission. The presence of one (1) parameter, clinical and/or imaging, in the Severe or High Risk for Mortality category is an indication for admission. This classification is not a pneumonia severity classification, rather it is a categorization of the risk of mortality from pediatric pneumonia. It utilizes clinical and diagnostic parameters to assign the patient to a risk level at point-of-care.

The aforementioned clinical parameters and imaging findings are predictors of high-risk for pneumonia-related mortality. To classify to a higher risk category, at least 1 clinical or ancillary parameter should be present. In the absence of an ancillary parameter, a clinical parameter may suffice.

<table>
<thead>
<tr>
<th># of studies included in MA or SR (and list of authors)</th>
<th>Study Design/s</th>
<th>Key findings</th>
<th>Grade level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>56 (Dean &amp; Florin,2018)</td>
<td>Systematic review of cohort and case-control studies</td>
<td>Multifocal disease and fluid bronchograms on transthoracic ultrasound are associated with severity (CHEN) – multifocal involvement was an independent risk factor for a poor outcome including:  - ICU admission (OR = 5.38)  - longer LOS (&gt;9 days) (OR = 9.75)  - tube thoracotomy (OR = 20.12) – fluid bronchogram was an independent predictor of a longer hospital stay (&gt; 9 days) (OR = 5.00) and tube thoracotomy (OR = 13.33) Moderate or large effusions were associated with ICU admission (CHEN) OR = 3.2; 95% CI = 1.1-8.9 and mechanical ventilation OR = 14.8; 95% CI = 9.8-22.4 Impaired perfusion on lung US – lung necrosis – a longer hospital stay would be expected if moderate-to-massive pleural effusion was observed in addition to impaired perfusion in ultrasonography (LAI) OR = 3.08; 95% CI = 1.15-8.29</td>
<td>Low</td>
</tr>
</tbody>
</table>
A patient classified as having non-severe PCAP would have a low risk for pneumonia-related mortality and may be treated in an outpatient basis with the recommended management plan. A caveat to this initial disposition would be a return to the facility for admission if there is no clinical improvement OR with signs of deterioration such as hypoxemia, chest indrawing/retractions, grunting, altered sensorium, pallor within 48 hours; OR if the patient refuses or is unable to feed, drink or take medications. Patients classified as having non-severe PCAP should also be admitted if they have an underlying medical condition that can aggravate the overall clinical status. Other relative indications for admission of non-severe PCAP patients are absence of a reliable caregiver, inability for close follow-up, and no easily accessible medical facility.

A patient classified as having severe PCAP would have a high risk for pneumonia-related mortality and should be admitted for close observation and immediate institution of the recommended management plan. The indications for admission to a critical care unit should also be noted and close monitoring must be performed as these patients are at greater risk for mortality.

REFERENCES


Clinical Question 3
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS, WHAT DIAGNOSTIC AIDS WILL CONFIRM THE PRESENCE OF NON-SEVERE COMMUNITY-ACQUIRED PNEUMONIA IN AN AMBULATORY SETTING?

BEATRIZ PRAXEDES APOLLA MANDANAS-PAZ, M.D.
MARION O. SANCHEZ, M.D.

KEY RECOMMENDATION

Routine diagnostic aids are not considered for non-severe PCAP in an ambulatory setting. (Conditional recommendation, Expert opinion)

SUMMARY OF EVIDENCE

No evidence was found regarding the use of diagnostic aids in confirming non-severe PCAP. Diagnostic aids are not routinely recommended in children with mild clinical presentation and managed in an ambulatory setting. It is the discretion of the attending physician to request for diagnostic aids based on his initial clinical assessment.
Clinical Question 4
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS, WHAT DIAGNOSTIC AIDS WILL CONFIRM THE PRESENCE OF SEVERE COMMUNITY-ACQUIRED PNEUMONIA IN A HOSPITAL SETTING?

BEATRIZ PRAXEDES APOLLA MANDANAS-PAZ, M.D.
MARION O. SANCHEZ, M.D.

KEY RECOMMENDATIONS

1. Chest X-ray is strongly recommended as an initial diagnostic aid for patients classified as having severe PCAP. (Strong recommendation, high-grade evidence)
2. Point-of-care chest ultrasonography (POCUS) performed by a skilled expert is strongly recommended as a diagnostic aid for patients classified as having severe PCAP. (Strong recommendation, high-grade evidence)
3. Procalcitonin (PCT) is recommended to be used in conjunction with other factors such as clinical presentation, imaging modalities and other laboratory aids in diagnosing bacterial PCAP. (Conditional recommendation, moderate-grade evidence)
4. Sputum Gram stain and culture are not considered to be done routinely in patients classified as having severe PCAP. (Conditional recommendation, low-grade evidence)
5. Complete blood count, arterial blood gas, serum electrolytes and other diagnostic aids are considered to be used as necessary based on the clinician’s evaluation. (Conditional recommendation, Expert opinion)

SUMMARY OF EVIDENCE

1. Chest radiography

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Positive diagnosis of pneumonia</th>
<th>Importance: Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>12 (Balk et al., 2017)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
<td>Chest X-ray is recommended as an initial test Sn: 86.80%. Sp: 98.20% LR (+): 48.22. LR (-): 0.13</td>
</tr>
</tbody>
</table>
2. Chest ultrasonography

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Positive diagnosis of pneumonia</th>
<th>Importance: Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>6 (Wang et al., 2019)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
<td>CUS(^6) as a diagnostic aid Sn: 86.80% Sp: 98.20% LR (+): 48.22 LR (-): 0.134</td>
</tr>
<tr>
<td>22 (Najgrodzka et al., 2019)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
<td>CUS as a diagnostic aid Sn: 96.70% Sp: 87.39% LR (+): 7.61 LR (-): 0.04</td>
</tr>
<tr>
<td>12 (Hua Xin et al., 2017)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
<td>CUS as a diagnostic aid Sn: 93.00% Sp: 96.00% LR (+): 23.25 LR (-): 0.07</td>
</tr>
<tr>
<td>6 (Zar et al., 2017)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
<td>CUS as a diagnostic aid Positive: 0.71 Negative: 0.80</td>
</tr>
</tbody>
</table>

3. Procalcitonin

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Positive diagnosis of pneumonia</th>
<th>Importance: Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>25 (Tsou et al., 2020)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
<td>PCT for bacterial pneumonia Sn: 64.00% Sp: 72.00% LR (+): 2.29 LR (-): 0.50</td>
</tr>
</tbody>
</table>

4. Sputum GS/CS

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Positive diagnosis of pneumonia</th>
<th>Importance: Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>21 (Ogawa et al., 2019)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
<td>Sputum Gram stain, culture, and sensitivity as a diagnostic aid for bacterial CAP S. pneumoniae Sn: 69.00 Sp: 91.00 LR (+): 7.67 LR (-): 0.34 H. influenzae Sn: 76.00 Sp: 97.00 LR (+): 25.33 LR (-): 0.25</td>
</tr>
</tbody>
</table>

\(^6\) CUS - chest ultrasound
CONTEXT AND CONSIDERATIONS

Chest radiography remains to be the initial diagnostic aid of choice for severe PCAP. Postero-anterior and lateral (PA-L) views are preferred for children who are able to stand upright, otherwise antero-posterior and lateral (AP-L) views are acceptable especially for younger infants. Proper patient positioning is vital to obtain a good quality chest radiograph. As best practice, consider having two (2) radiologists to review the X-ray images to eliminate intra-observer variability and encourage clinicians to review the radiographs for better clinical correlation.

In recent years, robust evidences show the value of chest ultrasonography as an initial tool in the diagnosis of PCAP. Zar et. al enumerated the advantages of point-of-care ultrasound (POCUS) in their study, namely: [1] it can be performed at point-of-care; [2] it is feasible and less costly than chest radiography; [3] it is less affected by movement or crying than other imaging modalities; [4] it can be done in sleeping children and [4] it is free of ionizing radiation. Operator dependency is one of the limitations often cited with regard to the ultrasound imaging study (Wang et al., 2019), other limitations include: [1] inability to visualize the whole lung at the same time or to identify consolidation deep within the lung parenchyma; (Zar et al., 2017) [2] subscapular or sub-clavicular consolidations that did not reach the pleura are inaccessible to ultrasound imaging and may be missed; (Najgrodzka et al., 2019) [3] the spleen or air in the stomach can be misinterpreted as lung consolidation with air bronchograms (Zar et al., 2017). The meta-analysis of Hua Xin et al. highlighted 4 major abnormalities that are frequently observed on CUS: pulmonary consolidation, positive air bronchogram, abnormal pleural line, and pleural effusion. Among these 4, positive air bronchogram and lung consolidation are the most often detected signs on CUS.

There is some evidence that procalcitonin (PCT) can be used to distinguish between bacterial and viral aetiology of pneumonia. PCT, a precursor of the calcitonin hormone, increases after exposure to bacterial endotoxins and inflammatory cytokines (Dandona et al. 1994). It is a favourable characteristic in a biomarker for diagnosis of bacterial infections, determination of disease severity, evaluation of patients’ response to treatment, and prevention of antibiotic overuse (Shcuetz, McCluskey et al., 2017). Current evidence on the other biomarkers such as CRP, plasma interferon-γ protein-10, chitinase 3-like-1, RNA biosignatures remain conflicting and overlapping (Principi et al., 2017).

Gram stain of expectorated sputum is an inexpensive, non-invasive, readily available test that can promptly identify causative bacteria if performed by an experienced observer in a qualified laboratory on good-quality specimens (Skerrett et al., 1999). A good-quality specimen is defined as one containing ≥25 leukocytes and <10 squamous epithelial cells per low power field (Ogawa et al., 2020). One meta-analysis was found advocating sputum GS, culture and sensitivity as a diagnostic aid for bacterial CAP. This study, though with modest limitation in terms of methodology, showed that sputum GS was highly specific to diagnose S. pneumoniae and H. influenzae infections in patients with CAP with values of 91% and 97% respectively. Sensitivity, on the other hand for the two microorganisms were 69% and 76%. Selecting good-quality specimens could increase this yield, although data supporting this are limited (Ogawa et al., 2020). There is insufficient evidence to support the routine use of culture and sensitivity of blood, tracheal aspirate, and bronchoalveolar lavage for the diagnosis of severe PCAP.
REFERENCES


Clinical Question 5
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT CLINICAL AND ANCILLARY PARAMETERS WILL DETERMINE THE NEED FOR ANTIBIOTIC TREATMENT?

MARK JOSEPH S. CASTELLANO, M.D.
FRANCESCA MAE T. PANTIG, M.D.
SUZANNE S. PONIO-DEGOLLADO, M.D.

KEY RECOMMENDATION

Empiric antibiotic therapy is considered to be started in patients with clinical signs and symptoms of PCAP with ANY of the following parameters suggestive of bacterial etiology for both non-severe and severe pneumonia: *(Conditional recommendation, low-grade evidence)*

1. Elevated white blood cell count (WBC)
2. Elevated C-reactive protein (CRP)
3. Elevated procalcitonin (PCT)
4. Imaging findings such as:
   4.1 Alveolar infiltrates in chest radiograph; or
   4.2 Unilateral, solitary lung consolidation and/or air bronchograms and/or pleural effusion in lung ultrasound

SUMMARY OF EVIDENCE

<table>
<thead>
<tr>
<th>Outcome: Differentiating bacterial from viral pneumonia using CBC, CRP, PCT</th>
<th>Importance: Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
</tr>
<tr>
<td>12 (Thomas et al., 2020)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age</th>
<th>Mean (x10^3/ml)</th>
<th>Range (x10^3/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 month</td>
<td>10.8</td>
<td>4.0 - 19.5</td>
</tr>
<tr>
<td>6 mos - 2 years</td>
<td>10.6</td>
<td>6.0 - 17.0</td>
</tr>
<tr>
<td>2 - 6 years</td>
<td>8.5</td>
<td>5.0 - 15.5</td>
</tr>
<tr>
<td>6 - 12 years</td>
<td>8.1</td>
<td>4.5 - 13.5</td>
</tr>
<tr>
<td>12 - 18 years</td>
<td>7.8</td>
<td>4.5 - 13.5</td>
</tr>
</tbody>
</table>

Reference: The Harriet Lane Handbook 22nd ed, 2021
| 25 (Po-Yang et al., 2020) | Meta-analysis of Cohort and Case-control studies | Procalcitonin showed moderate diagnostic accuracy for diagnosis of bacterial pneumonia in children, and may be used in conjunction with clinical presentation and laboratory and imaging findings prior to starting of antibiotics. Pooled Sn: 0.64 (95% CI: 0.53-0.74) Pooled Sp: 0.72 (95% CI: 0.64-0.79) Pooled +LR 2.3 (95% CI: 1.8-3.0) Pooled -LR: 0.50 (95% CI: 0.38-0.66) | Low |

| Zar, et. al., 2020 | CPG | General tests for infection, including acute-phase reactants (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), white cell count (WCC), neutrophil count and procalcitonin (PCT)) do not reliably differentiate bacterial from viral pneumonia and should not be routinely used. CRP concentrations ≥ 40 mg/L with radiological confirmation of pneumonia suggests bacterial pneumonia. | High |

| Tapiainen, et. al., 2016 | CPG | Elevated C-reactive protein concentrations or leucocyte counts increase the possibility of bacterial pneumonia, but low C-reactive protein concentrations or leucocytes do not exclude bacterial pneumonia. | High |

<table>
<thead>
<tr>
<th>Outcome:</th>
<th>Differentiating bacterial from viral pneumonia using imaging findings</th>
<th>Importance: Critical/Important</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>Buonsenso et al., 2021</td>
<td>individual cohort study</td>
<td>Differentiating bacterial from viral pneumonia: Large-sized consolidation: OR 13.62 (95% CI 1.16-159.88) Air bronchogram: OR 6.58 (95% CI 1.67-25.93) Pleural effusion: OR 1.48 (95% CI 0.42 - 5.16) Deep vertical artifacts: OR 0.27 (95% CI 0.07-1.06)</td>
</tr>
</tbody>
</table>

| Malla et al., 2020 | individual cross-sectional analytical study | Sn 91% (95% CI 84-96) Sp 91.3% (95% CI 84-96) PPV 91.9% (95% CI 85-96) NPV 90.3% (95% CI 82-95) | Very low |
| Berce et al., 2019 | Individual cohort study | Differentiating bacterial from viral pneumonia  
Unilateral consolidation:  
OR 12.42 (95% CI 4.59-33.62)  
PPV 65.7  
NPV 85.7  
Solitary consolidation:  
OR 9.01 (95% CI 3.94-20.60)  
PPV 71.3  
NPV 78.3  
Differentiating bacterial from atypical pneumonia:  
Unilateral consolidation:  
OR 9.41 (95% CI 2.80-31.66)  
PPV 65.7  
NPV 85.7  
Solitary consolidation:  
OR 8.86 (95% CI 2.96-26.51)  
PPV 71.3  
NPV 78.3 | Very low |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tapiainen, et al., 2016</td>
<td>CPG</td>
<td>Alveolar pneumonia is reliably detected in chest radiography, but interstitial changes are not so reliably diagnosed. Alveolar infiltrates suggest bacterial pneumonia.</td>
<td>High</td>
</tr>
</tbody>
</table>

**CONTEXT AND CONSIDERATIONS**

There is insufficient evidence to differentiate bacterial from viral pneumonia based on clinical signs and symptoms alone. In the absence of the aforementioned ancillary parameters, the decision to start antibiotics empirically is based on the clinician’s assessment and sound judgment. Efforts should be made to obtain evidence of the causative pathogen for PCAP to avoid unnecessary use of antibiotics and to provide optimal pathogen-directed care to patients.

Laboratory tests and chest imaging are not routinely requested prior to starting antibiotic therapy. If these ancillary tests are done, empiric antibiotics may be started in patients with clinical signs and symptoms of PCAP with elevated WBC for age, elevated CRP or elevated procalcitonin. However, a low or normal level of biomarkers does not exclude bacterial pneumonia. Furthermore, no optimal cut-off values for CRP and procalcitonin can be derived from the reviewed literature since different units, cut-off values and laboratory testing systems were used in the clinical setting. In patients with clinical signs and symptoms of PCAP, the presence of alveolar infiltrates, solitary lung consolidation or air bronchogram on chest radiograph and pleural effusion on lung ultrasound are suggestive of a bacterial etiology and warrants antibiotic use.
REFERENCES


Clinical Question 6A
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT EMPIRIC TREATMENT IS EFFECTIVE IF A BACTERIAL ETIOLOGY IS CONSIDERED?

RODALIZA R. MANGLICMOT-GUMBOC, M.D.
MELODY K. TOLENTINO, M.D.

KEY RECOMMENDATIONS

1. For patients classified as having non-severe PCAP, regardless of immunization status against *Streptococcus pneumoniae* and/or *Haemophilus influenzae* type b (Hib), any of the following is considered:
   1.1 start Amoxicillin trihydrate at 40-50mg/kg/day Q8 for 7 days OR at 80-90mg/kg/day Q12 for 5 to 7 days.
   1.2 start Amoxicillin-clavulanate at 80-90mg/kg/day Q12 (based on Amoxicillin content using a 14:1 amoxicillin:clavulanate formulation) for 5 to 7 days OR Cefuroxime at 20-30mg/kg/day Q12 for 7 days in settings with documented high-level penicillin-resistant pneumococci or beta-lactamase-producing *H. influenzae* based on local resistance data or hospital antibiogram.

   (Conditional recommendation, low-grade evidence)

2. For patients classified as having severe PCAP, regardless of immunization status against *Streptococcus pneumoniae*, any of the following is considered:
   2.1 start Penicillin G at 200,000 units/kg/day Q6 if with complete *Haemophilus influenzae* type b (Hib) vaccination OR Ampicillin at 200mg/kg/day Q6 if with no or incomplete or unknown *Haemophilus influenzae* type b (Hib) vaccination
   2.2 start Cefuroxime at 100-150mg/kg/day Q8 OR Ceftriaxone at 75-100mg/kg/day Q12 to Q24 OR Ampicillin-sulbactam at 200mg/kg/day Q6 (based on ampicillin content) in settings with documented high-level penicillin-resistant pneumococci or beta-lactamase-producing *H. influenzae* based on local resistance data or hospital antibiogram
   2.3 add Clindamycin at 20-40mg/kg/day Q6 to Q8 when *Staphylococcal* pneumonia is highly suspected based on clinical and chest radiograph features. However, in cases of severe and life-threatening conditions such as sepsis and shock, Vancomycin at 40-60 mg/kg/day Q6 to Q8 is preferred.

   (Conditional recommendation, low-grade evidence)
3. For patients with known hypersensitivity to penicillin, classified as
   3.1 Non-type 1 hypersensitivity to Penicillin, cephalosporins such as Cefuroxime PO 20-30mg/kg/day Q12 or IV 100-150mg/kg/day Q8 OR Ceftriaxone at 75-100mg/kg/day Q12 to Q24 is considered.
   3.2 Type 1 hypersensitivity to Penicillin (immediate, anaphylactic-type), any of the following is considered:
      3.2.1 Azithromycin at 10mg/kg/day PO or IV Q24 for 3 days OR 10mg/kg/day on day 1 followed by 5 mg/kg/day Q24 for days 2 to 5
      3.2.2 Clarithromycin at 15mg/kg/day Q12 for 7 days
      3.2.3 Clindamycin at 10-40mg/kg/day PO or 20-40mg/kg/day IV Q6 to Q8 for 7 days  
         (Conditional recommendation, low-grade evidence)

4. When an atypical pathogen is highly suspected, starting a macrolide is considered as follows:
   4.1 Azithromycin at 10mg/kg/day PO or IV Q24 for 5 days, particularly in infants less than 6 months old whom pertussis is entertained, OR 10mg/kg/day Q24 for 3-5 days OR 10mg/kg/day on day 1 followed by 5 mg/kg/day Q24 for days 2 to 5
   4.2 Clarithromycin at 15mg/kg/day Q12 for 7 to 14 days
      (Conditional recommendation, low-grade evidence)

5. When a specific pathogen is identified, modifying the empiric treatment based on the antibiotic susceptibility pattern and/or the drug of choice is recommended.
      (Strong recommendation, high-grade evidence)

6. When treating for uncomplicated bacterial PCAP, 7 to 10 days treatment is considered but a longer duration may be required depending on the patient’s clinical response, virulence of the causative organism and eventual development of complications.
      (Conditional recommendation, low-grade evidence)

SUMMARY OF EVIDENCE

Antimicrobial Resistance Surveillance Pattern from 2016 to 2020 [https://arsp.com.ph/]

<table>
<thead>
<tr>
<th>Streptococcus pneumoniae</th>
<th>ALL ISOLATES</th>
<th>RESPIRATORY ISOLATES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>69% resp.</td>
<td>66% resp.</td>
</tr>
<tr>
<td>penicillin (nm)</td>
<td>6.1%</td>
<td>10%</td>
</tr>
<tr>
<td>chloramphenicol</td>
<td>3.4%</td>
<td>4.8%</td>
</tr>
<tr>
<td>cotrimoxazole</td>
<td>18.1%</td>
<td>15.1%</td>
</tr>
<tr>
<td>erythromycin</td>
<td>7%</td>
<td>9.8%</td>
</tr>
<tr>
<td>ceftriaxone (nm)</td>
<td>3%</td>
<td>1.2%</td>
</tr>
<tr>
<td>levofloxacin</td>
<td>1.1%</td>
<td>0.8%</td>
</tr>
<tr>
<td>clindamycin</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
### Haemophilus influenzae

<table>
<thead>
<tr>
<th></th>
<th>ALL ISOLATES</th>
<th>RESPIRATORY ISOLATES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>94% resp.</td>
<td>95% resp.</td>
</tr>
<tr>
<td>2016</td>
<td>2017</td>
<td>2018</td>
</tr>
<tr>
<td>ampicillin</td>
<td>7.8%</td>
<td>14%</td>
</tr>
<tr>
<td>amoxicillin-clavulanate</td>
<td>5.8%</td>
<td>-</td>
</tr>
<tr>
<td>ampicillin-sulbactam</td>
<td>-</td>
<td>5%</td>
</tr>
<tr>
<td>chloramphenicol</td>
<td>5.3%</td>
<td>9%</td>
</tr>
<tr>
<td>cefuroxime</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ceftriaxone</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>levofloxacin</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>azithromycin</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

### Staphylococcus aureus

<table>
<thead>
<tr>
<th></th>
<th>ALL ISOLATES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>resp. 19%</td>
</tr>
<tr>
<td>2016</td>
<td>2017</td>
</tr>
<tr>
<td>oxacillin</td>
<td>61.5%</td>
</tr>
<tr>
<td>cotrimoxazole</td>
<td>24.6%</td>
</tr>
<tr>
<td>clindamycin</td>
<td>11.4%</td>
</tr>
<tr>
<td>vancomycin</td>
<td>0.8%</td>
</tr>
<tr>
<td>linezolid</td>
<td>1.4%</td>
</tr>
</tbody>
</table>

### SUMMARY OF EVIDENCES

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Etiology</th>
<th># of studies included in SR/MA and authors</th>
<th>Study Design/s</th>
<th>Key Findings</th>
<th>Importance: Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>H. influenzae, S. aureus and S. pneumoniae were the most commonly detected bacteria</td>
<td>Very low</td>
</tr>
<tr>
<td>1</td>
<td>Nathan, et.al. 2020</td>
<td>Cohort</td>
<td></td>
<td>The most frequently detected bacterial pathogens were K. pneumoniae, S. pneumoniae, H. influenzae and S. aureus</td>
<td>Very low</td>
</tr>
<tr>
<td>48</td>
<td>Ning, et.al., 2017</td>
<td>Meta-analysis of Cohort studies</td>
<td></td>
<td>The most common detected bacterial pathogen obtained through nasopharyngeal swab and BAL were S. pneumoniae and non-type b H. influenzae followed by K. pneumoniae and MSSA</td>
<td>Very low</td>
</tr>
<tr>
<td>1</td>
<td>Das, et.al. 2016</td>
<td>Cohort</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome</td>
<td>Treatment, Dose and Duration of Therapy</td>
<td>Importance:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>South African Thoracic Society Guidelines (Reubenson et al., 2020)</strong></td>
<td><strong>CPG</strong></td>
<td><strong>critical</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Oral amoxicillin is recommended for children &gt;1 month of age who do not require hospitalization</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. For ambulatory treatment of pneumonia, amoxicillin (45 mg/kg/dose 12-hourly) remains the preferred antibiotic for children &gt;1 month old.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Treatment duration should be 5 days, but longer duration may be needed in children with severe or complicated disease.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. Bacteremic staphylococcal pneumonia should be treated for 14-28 days, dependent on complications and response to treatment while uncomplicated presumed staphylococcal pneumonia (blood culture negative) may be managed with 10-day course of targeted antibiotic therapy, depending on clinical response.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5. If cultures are positive, use targeted therapy according to organism’s susceptibility pattern.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6. Macrolide antibiotics should be used if pertussis, Mycoplasma or Chlamydia is suspected (evidence level IVa) such as Azithromycin 10mkd daily for 5 days, or Clarithromycin 15mkd Q12 for 10days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chou et al, 2019</strong></td>
<td><strong>CPG</strong></td>
<td><strong>High</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Empiric therapy for outpatient treatment of CAP in children for presumed atypical pneumonia is macrolides, Azithromycin 10mkd daily for 3-5 days and Clarithromycin 15mkd Q12 for 7-14 days.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Targeted therapy for treatment of CAP in children with atypical organisms such as Mycoplasma and Chlamydophila are Azithromycin and Clarithromycin with 3 to 7 days treatment duration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1 (Mathur et al., 2017)</strong></td>
<td><strong>Evidence review</strong></td>
<td><strong>Low</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2014 revision preferred oral amoxicillin to oral cotrimoxazole for the treatment of fast-breathing pneumonia and was equivalent to injectable penicillin/ampicillin in cases of chest-indrawing pneumonia.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1 (Messinger et al. 2021)</strong></td>
<td><strong>Evidence review</strong></td>
<td><strong>Low</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Length of therapy for uncomplicated bacterial CAP should not exceed 7 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. similar success rates of 7 days when compared with 10 days and 5 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1 (Leung, et.al., 2018)</strong></td>
<td><strong>Evidence review</strong></td>
<td><strong>Low</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. In previously healthy children under the age of 5 years, high dose amoxicillin is the treatment of choice.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. For those with type 1 hypersensitivity to penicillin, clindamycin, azithromycin, clarithromycin, and levofloxacin are reasonable alternatives.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. For children with a non-type 1 hypersensitivity to penicillin, cephalosporins should be considered.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Paediatric community-acquired pneumonia A and B can be treated as efficaciously with either high-dose (80mkd in 2 divided doses for 5 days) or standard-dose (40mkd in 3 divided doses for 7 days) Amoxicillin. No significant difference in the clinical course of the 2 groups by days 3 and 7 and frequency of adverse events were also similar.

CONTEXT AND CONSIDERATIONS

The causative agents of community acquired pneumonia vary according to age of the child and the setting in which the infection is acquired. Generally, viruses notably Respiratory Syncytial Virus (RSV), are the most common cause of pneumonia in children younger than 5 years. *Streptococcus pneumoniae* is the most common bacteria across all age groups. Other important bacterial causes in children younger than 5 years include *Hemophilus influenzae*, *Streptococcus pyogenes* and *Moraxella catarrhalis*. In children 5 years and older, other important causes include *Mycoplasma* and *Chlamydophila*.

The advent of universal childhood immunization with pneumococcal and Hib conjugate vaccines have resulted in a shift in bacterial etiology, with non-typeable *H. influenzae* and *Staphylococcus aureus* causing a greater proportion of severe pneumonia in hospitalized children worldwide.

With the global emergence of antimicrobial resistance, judicious use of antibiotics cannot be overemphasized. The choice of empiric antibiotics in PCAP should always be guided by the general principles of rational antibiotic use and the most likely pathogen should be considered. Starting with broad spectrum antibiotics to treat uncomplicated PCAP is highly discouraged and such antibiotics should be reserved for more complicated forms of the disease and for drug-resistant pathogens. Amoxicillin is still the treatment of choice because it is effective against the majority of pathogens causing CAP in this age group. High-dose amoxicillin is recommended for treatment of suspected or confirmed penicillin-resistant *S. pneumoniae*; the resistance of which can be overcome at higher drug concentrations. Practitioners commonly presume that oral cephalosporins are superior to amoxicillin for *S. pneumoniae*; this likely stems from the knowledge that some penicillin-resistant pneumococci isolates are susceptible to ceftriaxone hence, oral cephalosporins are assumed superior to amoxicillin. However, oral cephalosporins have short half-lives, highly protein bound and often have long dosing intervals. This results in serum concentrations that do not provide enough bactericidal time. Because the pharmacokinetics of the oral cephalosporins are far inferior to amoxicillin, their use in CAP should be reserved for patients who are allergic to penicillin or patients with isolates known to be resistant to amoxicillin but susceptible to cephalosporins such as *M. catarrhalis* or beta-lactamase-positive *H. influenzae*. When atypical pathogens are highly suspected especially in a child who is not ill-looking despite having clinical pneumonia (“walking pneumonia”), although clinical presentation may be indistinguishable with viral pneumonia, starting a macrolide may be considered.
Staphylococcal pneumonia may present with high fever or hypothermia, cough, respiratory distress, signs of shock, and or with presence of skin lesions (point of bacterial entry). However, skin lesions may also be absent in other instances. Pulmonary auscultation is often normal; sometimes with dullness indicating pleural effusion. Typical chest radiographic findings may show multi-lobar consolidation with cavitation, pneumatoceles and/or spontaneous pneumothorax. Other bacterial agents, however, may have similar imaging findings.

There is no definite recommendation for an acceptable antimicrobial resistance rate, but some literature state that between 10-20% is tolerable. Allowable resistance rate will also depend on certain factors such as local resistance data and hospital antibiograms as this varies from place to place and over time.

Currently, there is no defined optimal duration of antibiotic therapy in PCAP. Most experts and guidelines recommend that 7 to 10 days antibiotic treatment is appropriate for most uncomplicated PCAP. However, treatment duration should be extended as necessary depending on the patient’s clinical response, virulence of the causative organism and eventual development of complications. Recent studies are now looking into shortening the duration of antibiotic therapy especially in non-severe cases of PCAP.
REFERENCES


National Antibiotic Guidelines 2018

Kleinman, K, McDaniel, L, Molloy, M. The Harriet Lane Handbook 22nd Ed. Inter’l. 2021
Clinical Question 6B
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH BACTERIAL COMMUNITY-ACQUIRED PNEUMONIA, WILL THE ADDITION OF A MACROLIDE TO STANDARD EMPIRIC REGIMEN IMPROVE TREATMENT OUTCOME?

KRISTINE ALVARADO - DELA CRUZ, M.D.
LESLEY ANNE DELA CRUZ, M.D.

KEY RECOMMENDATION

The addition of a macrolide to standard beta-lactam antibiotic therapy is not considered in the empiric treatment of bacterial PCAP. (Conditional recommendation, very low-grade evidence)

SUMMARY OF EVIDENCE

Outcomes of studies which did not recommend the use of macrolides

<table>
<thead>
<tr>
<th>Outcome 1: Macrolide resistance</th>
<th>Importance: CRITICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
</tr>
<tr>
<td>24 (Chen et al., 2020)</td>
<td>Meta-analysis of Randomized trials</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Outcomes of studies which recommended the use of macrolides

<table>
<thead>
<tr>
<th>Outcome 2: Length of hospitalization</th>
<th>Importance: NOT CRITICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
</tr>
<tr>
<td>8 (Lin et al., 2018)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Individual cohort study</td>
<td>Treatment failure: 14 Day TF: 1 to &lt;6 years OR 1.34, 95%CI = 0.83-2.18, 6-18 years OR 0.51, 95%CI = 0.28-0.95</td>
</tr>
<tr>
<td>Individual cohort study</td>
<td>Time to discharge (reported in hazard ratio and 95%CI) HR (Propensity score-matched): 0.92, 95%CI = 0.77-1.08, HR (Propensity score-weighted): 0.92, 95%CI = 0.79-1.07</td>
</tr>
<tr>
<td>Treatment failure</td>
<td></td>
</tr>
</tbody>
</table>

**CONTEXT AND CONSIDERATIONS**

There is some evidence on the empiric use of macrolides as an add-on therapy to beta-lactams for non-severe PCAP in patients >5 years of age to cover for atypical pathogens when suspected. However, this practice is not routinely recommended, considering that several studies attest that it is difficult to clinically distinguish signs and symptoms definitive to the diagnosis of atypical pneumonia, and that the inadvertent use of macrolides have the potential to induce macrolide resistance.
REFERENCES


Clinical Question 7
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT TREATMENT IS EFFECTIVE IF A VIRAL ETIOLOGY IS CONSIDERED?

ANGELYN A. CORONEL, M.D.
MARIA ANGELA NICOLE S. PERRERAS, M.D.

KEY RECOMMENDATION

Oseltamivir is strongly recommended to be started immediately within 36 hours of laboratory-confirmed influenza infection. *(Strong recommendation, high-grade evidence)*

SUMMARY OF EVIDENCE

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Reduction in the duration of illness</th>
<th>Importance: CRITICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>5 (Malosh et al., 2018)</td>
<td>Meta-analysis of Randomized trials</td>
<td>Significant reduction in the duration of illness among those who received timely oseltamivir treatment (RMST difference -17.6 hours, (95% CI, -34.5 to -0.7 hours).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stratified analysis: Observed larger RMST for individual who received early treatment (&lt;24 hours compared to those who received treatment 24 to 48 hours after the onset (-22 hours, (95% CI, -29.4 to 16.2 hours VS -4.4 hours, 95% CI, -15.5 to 6.5 hours)</td>
</tr>
<tr>
<td>20 (Jefferson et al., 2014)</td>
<td>Meta-analysis of Randomized trials</td>
<td>Oseltamivir in healthy children reduced the time to first alleviation of symptoms with mean difference of 29 hours, (95% confidence interval 12 to 72 hours (p=0.001)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospitalization No significant effect on hospitalization. Risk difference (RD) 0.15%(95% CI -0.78 to 0.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pneumonia Oseltamivir significantly reduced self-reported, investigator mediated, unverified pneumonia.</td>
</tr>
</tbody>
</table>
No oseltamivir treatment studies reported effects on radiologically confirmed pneumonia

Harm of treatment
In children, induced vomiting (RD 5.34%, 94% CI 1.75 to 10.29)

CONTEXT AND CONSIDERATIONS

Recommendations on the treatment of viral pneumonia are limited by the availability of laboratory confirmation for influenza and the available antiviral treatments accessible to clinicians. As of this writing, only oseltamivir is available locally as treatment for influenza.

Laboratory confirmation for influenza may be costly and is not widely available in all healthcare facilities. These point-of-care tests, when available, are helpful in initiating early therapy and decreasing the use of unnecessary diagnostics and antibiotics. These point of care tests include influenza point of care kits and the multiplex respiratory panel. This respiratory panel uses nasopharyngeal specimens to detect 4 bacteria and 18 respiratory viruses, including SARS-CoV2. It has an overall sensitivity of 97.1% and specificity of 99.3%.

Treatment for suspected or confirmed influenza is recommended in those with severe illness, i.e., those who are admitted in the hospital, have serious complications like myocarditis and encephalitis, or who are clinically deteriorating. While for non-severe illness suspected with viral pneumonia, treatment is indicated in 1) high-risk children such as those less than five years old, especially those under 2 years old, or those with other comorbidities, and 2) children with high-risk contacts to reduce amount of viral shedding and decreasing risk of transmission to high-risk contacts.

Laboratory-confirmed influenza should be treated with oseltamivir. Timing of treatment should be within 48 hours of symptoms. Early antiviral treatment has been shown to provide maximal benefit. Initiating treatment beyond 48 hours of symptom onset may still provide clinical benefit in hospitalized children or those with serious complications or deteriorating disease. Treatment of oseltamivir is given twice a day for 5 days with the following doses: (1) for children younger than 1 year old, 3mg/kg/dose; (2) for 1 year and older, dose varies by child’s weight: for 15kg or less, 30mg; for >15 to 23 kg, 45mg; for >23 to 40kg, 60mg; and for >40kg, the dose is 75mg.

Antiviral may be considered in the following circumstances: (1) any previously healthy, symptomatic outpatient not at high-risk for complications in whom influenza is suspected or confirmed if treatment can be given within 48 hours; and (2) children with suspected or confirmed influenza disease whose siblings/household contacts are less than 6 months old or at high risk for influenza complications.

Immunization status for influenza for the year should not influence decision to initiate treatment with oseltamivir if influenza is highly considered.
REFERENCES


Clinical Question 8
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT CLINICAL AND ANCILLARY PARAMETERS WILL DETERMINE A GOOD RESPONSE TO CURRENT THERAPEUTIC MANAGEMENT?

RAYMUND ANTHONY L. MANUEL, M.D.
CATHERINE S. PALAYPAYON, M.D.
JEROME V. SENEN, M.D.

KEY RECOMMENDATIONS

1. For patients classified as having non-severe PCAP, good clinical response to current therapeutic management is considered when clinical stability is sustained for the immediate past 24 hours as evidenced by improvement of cough or normalization of core body temperature in Celsius in the absence of antipyretics within 24-72 hours after initiation of treatment. (Conditional recommendation, very low-grade evidence)

2. For patients classified as having severe PCAP, good clinical response to current therapeutic management is considered when clinical stability is sustained for the immediate past 24 hours as evidenced by ANY ONE of the following physiologic and ancillary parameters observed within 24-72 hours after initiation of treatment:
   2.1 Absence or Resolution of hypoxia
   2.2 Absence or Resolution of danger signs
   2.3 Absence or Resolution of tachypnea
   2.4 Absence or Resolution of fever
   2.5 Absence or Resolution of tachycardia
   2.6 Resolving or Improving radiologic pneumonia
   2.7 Resolving or Absent chest ultrasound findings
   2.8 Normal or Decreasing CRP
   2.9 Normal or Decreasing PCT
   (Conditional recommendation, very low-grade evidence)

---

8 Hypoxia is defined as having peripheral O2 saturation less than 95% at room air.
9 Danger signs are nasal flaring, grunting, head bobbing, cyanosis.
10 Respiratory rate taken at full minute based on the WHO-defined, age-specific values for tachypnea.
11 Fever is defined as having a core body temperature of 38 degrees Celsius and above
12 Cardiac rate taken at full minute based on Pediatric Advanced Life Support age-based values for tachycardia
13 Chest ultrasound findings include fluid bronchogram (presence of fluid in the airways), multifocal involvement, and pleural effusion.
## SUMMARY OF EVIDENCE

### Outcome 1
**Time to recovery and treatment failure**

<table>
<thead>
<tr>
<th># of studies included in MA or SR (and list of authors)</th>
<th>Study Design/s</th>
<th>Key findings</th>
<th>Grade level of evidence</th>
</tr>
</thead>
</table>
| 1 (Basnet et al., 2015)                                 | Individual cohort study | Absence of hypoxia (SpO2 < 90%) OR 0.52 (1.33, 2.74), p < 0.001  
Absence of any danger sign (nasal flaring, grunting, head bobbing, cyanosis) OR 0.61 (1.18, 2.32), p = 0.004  
Absence of radiologic pneumonia OR 0.45 (1.49, 3.31), p < 0.001 | Moderate |

### Outcome 2
**Disease progression or complicated pneumonia**

<table>
<thead>
<tr>
<th># of studies included in MA or SR (and list of authors)</th>
<th>Study Design/s</th>
<th>Key findings</th>
<th>Grade level of evidence</th>
</tr>
</thead>
</table>
| 1 (Chen et al., 2017)                                  | Individual cohort study | Absent multifocal involvement and ICU admission OR 0.19, p = 0.0027  
Absent multifocal involvement and LOS > 9 days OR 0.10, p = 0.02  
Absent pleural effusion and LOS > 9 days OR 0.17, p = 0.003  
Absent fluid bronchogram and LOS > 9 days OR 0.20, p = 0.006  
Absent multifocal involvement and tube thoracotomy OR 0.05, p = 0.0262  
Absent fluid bronchogram and tube thoracotomy OR 0.08, p = 0.0262 | Low |
| 1 (Erdman et al., 2015)                                | Individual cohort study | End-point pneumonia vs normal CXR using CRP  
Sn 80%  
+LR 3.8  
End-point pneumonia vs normal CXR using PCT  
Sn 70%  
+LR 2.3 | Very Low |
<table>
<thead>
<tr>
<th></th>
<th>Individual observational cohort</th>
<th>Median time of normalization of physiologic parameters (in hours, CI 95%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>(Wolf et al., 2015)</td>
<td><strong>Age &lt;2years</strong>&lt;br&gt;Fever: 14.5 (4.5-45.3)&lt;br&gt;Tachycardia: 4.5 (0.3-18.4)&lt;br&gt;Tachypnea: 38.6 (18.7-68.9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Age 2-4 years</strong>&lt;br&gt;Fever: 18.4 (2.8-42.8)&lt;br&gt;Tachycardia: 21.8 (5.7-51.9)&lt;br&gt;Tachypnea: 31.6 (9.5-61.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Age 5-17 years</strong>&lt;br&gt;Fever: 10.6 (0.8-34)&lt;br&gt;Tachycardia: 18 (5.8-42.2)&lt;br&gt;Tachypnea: 24.3 (10.8-59.2)</td>
<td>Low</td>
<td></td>
</tr>
</tbody>
</table>

**CONTEXT AND CONSIDERATIONS**

It is important to define several terms that are used in these recommendations. *Absolute clinical stability* is defined as the resolution of ALL pneumonia-associated signs and symptoms AND recovery to pre-pneumonia health status. *Approaching clinical stability* is defined as resolution of ANY pneumonia-associated sign or symptom OR delayed recovery to pre-pneumonia health status.

It is also important to note that even if absence of radiographic pneumonia on repeat chest X-ray is one of the ancillary parameters that determines good response to therapeutic management, performing a follow-up chest X-ray is not routinely done as long as there is clinical improvement as evidenced by the physiologic parameters mentioned.

**REFERENCES**


Clinical Question 9
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS WITH COMMUNITY-ACQUIRED PNEUMONIA, WHAT CAN BE DONE IF THE PATIENT IS NOT RESPONDING TO CURRENT THERAPEUTIC MANAGEMENT?

RAYMUND ANTHONY L. MANUEL, M.D.  
CATHERINE S. PALAYPAYON, M.D.  
JEROME V. SENEN, M.D.

KEY RECOMMENDATIONS

1. For patients classified as having non-severe PCAP and are not improving or clinically worsening within 24-72 hours after initiating therapeutic management, diagnostic evaluation is considered to determine if any of the following is present: (Conditional recommendation, low-grade evidence)

   1.1. Coexisting or other etiologic agents
   1.2. Etiologic agent resistant to current antibiotic, if being given
   1.3. Other diagnosis
       1.3.1. Pneumonia-related complication
           i. Pleural effusion
           ii. Necrotizing pneumonia
           iii. Lung abscess
       1.3.2. Asthma
       1.3.3. Pulmonary tuberculosis

2. For patients as having non-severe PCAP and are not improving or clinically worsening within 24-72 hours after initiating a therapeutic management,

   2.1 and started on standard dose Amoxicillin at 40-50mg/kg/day, increasing the dose to 80-90mg/kg/day Q12 OR shifting to Amoxicillin-Clavulanate at 80-90mg/kg/day (based on Amoxicillin content using a 14:1 amoxicillin:clavulanate formulation) Q12 OR Cefuroxime at 20-30 mg/kg/day Q12 is considered.

   2.2 and started on high-dose Amoxicillin, Amoxicillin-Clavulanate or Cefuroxime, admitting the patient for parenteral antibiotics is considered.

   2.3 adding a macrolide is considered when an atypical pathogen is highly suspected:

       2.3.1 Azithromycin at 10mg/kg/day PO or IV Q24 for 5 days, particularly in infants less than 6 months old whom pertussis is entertained, OR 10mg/kg/day Q24 for 3-5 days OR 10mg/kg/day on day 1 followed by 5 mg/kg/day Q24 for days 2 to 5
       2.3.2 Clarithromycin at 15mg/kg/day Q12 for 7 to 14 days

   (Conditional recommendation, low-grade evidence)
3. For patients classified as having severe PCAP and are not improving or clinically worsening, within 24-72 hours after initiating a therapeutic management, diagnostic evaluation is considered to determine if any of the following is present:
   3.1 Coexisting or other etiologic agents
   3.2 Etiologic agent resistant to current antibiotic, if being given
   3.3 Other diagnosis
      3.3.1 Pneumonia-related complication
          i. Pleural effusion
          ii. Pneumothorax
          iii. Necrotizing pneumonia
          iv. Lung abscess
      3.3.2 Asthma
      3.3.3 Pulmonary tuberculosis
      3.3.4 Sepsis
         *(Conditional recommendation, Expert opinion)*

4. The following diagnostic evaluations are considered in the presence of treatment failure in severe PCAP:
   4.1 Cultures
   4.2 Nucleic acid amplification test (e.g. PCR)
   4.3 Serology
   4.4 Imaging modalities: (chest radiography, UTZ or CT scan)
   4.5 Biomarkers (e.g. CBC, CRP, PCT)
      *(Conditional recommendation, Expert opinion)*

5. For patients that are not improving or clinically worsening within 24-72 hours after initiating a therapeutic management, a referral to a specialist is considered.
   *(Conditional recommendation, Expert opinion)*

**CONTEXT AND CONSIDERATIONS**

The recommendations as to the clinical approach to take for the different severities of pediatric community-acquired pneumonia are all based on expert opinion and would still warrant validation studies. Each clinical scenario of non-response to treatment may warrant different approaches hence studies designed to individualize the clinical pathways and validate their effectiveness need to be undertaken.

Regarding ancillary work-up, performing a blood culture is not routinely done in pediatric patients with community-acquired pneumonia, especially in non-severe cases, as studies have shown a low positive culture yield of only 0.4% to 2.5% of cases. However, if a patient is classified as having severe pneumonia and is suspected have concomitant septicemia or bacteremia, blood culture and sensitivity is considered. Other appropriate cultures may be included and are not limited to sputum, bronchoalveolar lavage and endotracheal aspirates.
REFERENCES


Clinical Question 10
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS, WHAT CLINICAL PARAMETERS WILL DETERMINE THAT SWITCH THERAPY CAN BE CONSIDERED IN THE MANAGEMENT OF SEVERE COMMUNITY-ACQUIRED PNEUMONIA?

MAYLENE M. AGRIMANO, M.D.
MA. KРИSTINA U. TORIO, M.D.

KEY RECOMMENDATION

Switch therapy is considered among patients with bacterial PCAP when ALL of the following clinical parameters are present:
1. Current parenteral antibiotic has been given for at least 24 hours
2. Afebrile for at least 8 hours without the use of any antipyretic drug
3. Able to feed and without vomiting or diarrhoea
4. Presence of clinical improvement as defined by ALL of the following:
   4.1 Absence of hypoxia
   4.2 Absence of danger signs
   4.3 Absence of tachypnoea
   4.4 Absence of fever
   4.5 Absence of tachycardia
   (Conditional recommendation, low-grade evidence)
## SUMMARY OF EVIDENCE

### RECOMMENDATION:

1. Current parenteral antibiotic has been given for at least 24 hours
2. Afebrile for at least 8 hours without the use of any antipyretic drug
3. Able to feed and without vomiting or diarrhea

<table>
<thead>
<tr>
<th>Outcome 1</th>
<th>Length of hospital stay and Readmission rate (within 30 days upon discharge)</th>
<th>Importance: CRITICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>1 (In-iw et al. 2015)</td>
<td>Individual randomized trial</td>
<td>Length of hospital stay: Conventional therapy: 4.77+1.5 days Switch therapy: 3.8+1.6 days P value 0.019 Readmission rate: Conventional therapy: 1 (3.8%) Switch therapy: 2 (6.5%) P value 0.66</td>
</tr>
</tbody>
</table>

### RECOMMENDATION:

Presence of clinical improvement as defined by ALL of the following:
Absence of hypoxia, danger sign, tachypnoea, fever, tachycardia

<table>
<thead>
<tr>
<th>Outcome 1</th>
<th>Time to recovery and treatment failure</th>
<th>Importance: CRITICAL</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>1 (Basnet et al., 2015)</td>
<td>Cohort</td>
<td>Absence of hypoxia (SpO2 &lt; 90%) OR 0.52 (1.33, 2.74) p &lt;0.001 Absence of any danger sign (nasal flaring, grunting, head bobbing, cyanosis) OR 0.61 (1.18, 2.32) p = 0.004</td>
</tr>
<tr>
<td>Outcome 2</td>
<td>Physiologic Parameters and Time to clinical stability</td>
<td>Importance: CRITICAL</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>1 (Wolf et al., 2015)</td>
<td>Individual observational cohort</td>
<td>Median time of normalization of physiologic parameters (in hours, CI 95%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Age &lt;2 years</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fever: 14.5 (4.5-45.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachycardia: 4.5 (0.3-18.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachypnea: 38.6 (18.7-68.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Age 2-4 years</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fever: 18.4 (2.8-42.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachycardia: 21.8 (5.7-51.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachypnea: 31.6 (9.5-61.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Age 5-17 years</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fever: 10.6 (0.8-34)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachycardia: 18 (5.8-42.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachypnea: 24.3 (10.8-59.2)</td>
</tr>
</tbody>
</table>

**CONTEXT AND CONSIDERATIONS**

Switch therapy is an approach in the management involving discontinuation of intravenous (IV) antibiotics and be shifted to oral antibiotics as soon as the patient’s condition allows. The choice of antibiotics from intravenous to oral must take into account the appropriate antibacterial spectrum, the pharmacokinetics and pharmacodynamics, and should have proven clinical efficacy in the condition being treated. There is no new evidence found for this clinical question, hence, the TWG decided to carry over the recommendations in the 2016 CPG update. The first three recommendations are taken from the inclusion criteria of the RCT done by Iniw, et al., comparing the treatment outcomes of switch therapy and conventional therapy in pediatric patients with community-acquired pneumonia who required hospitalization. The clinical outcomes showed that there was statistically significant reduction in length of hospital stay found in the switch therapy group (p = 0.019), whereas the readmission rate for both groups was not significantly different (p = 0.66). Furthermore, switch therapy can also be considered in the presence of clinical improvement as defined in the studies of Basnet et al. and Wolf et al. as absence of danger signs and hypoxia and normalization of fever, tachypnea and tachycardia, respectively. The advantages of switch therapy include reduced length of hospital stay which can lead to lesser risk of infections from infected IV lines and hospital pathogens and reduced cost. In an observational study of Sharma, et al., the switch therapy group showed lower number of complications but there was no difference in treatment outcome when compared to the standard treatment group. Restricted and monitored antibiotics should follow the DOH-Antimicrobial Stewardship Manual of Procedures regarding switch therapy.
REFERENCES


Clinical Question 11
AMONG INFANTS AND CHILDREN AGED 3 MONTHS TO 18 YEARS, WHAT ADJUNCTIVE TREATMENT IS EFFECTIVE FOR COMMUNITY-ACQUIRED PNEUMONIA?

KAREN NICOLE C. LLAMAS, M.D.
GRACE V. MALAYAN, M.D.

KEY RECOMMENDATIONS

1. Vitamins A is strongly recommended as adjunctive treatment for measles pneumonia. *(Strong recommendation, high-grade evidence)*

2. Zinc is not considered as adjunctive treatment for severe PCAP as it does not have any effect in shortening recovery time. *(Conditional recommendation, low-grade evidence)*

3. Vitamin D is not considered as adjunctive treatment for severe PCAP as it does not reduce the length of hospital stay. *(Conditional recommendation, low-grade evidence)*

4. Bronchodilators are considered as adjunctive treatment for PCAP in the presence of wheezing. *(Conditional recommendation, expert opinion)*

5. Mucokinetic, secretolytic, and mucolytic agents are not considered as adjunctive treatment for PCAP. *(Conditional recommendation, low-grade evidence)*

6. There is insufficient evidence to recommend the use of the following as adjunctive treatment for PCAP: *(Very low-grade evidence)*
   6.1 Oral folate
   6.2 Probiotics
   6.3 Vitamin C
   6.4 Virgin coconut oil (VCO)
   6.5 Nebulization with saline solution
   6.6 Steam inhalation
## SUMMARY OF EVIDENCE

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Treatment success</th>
<th>Importance:</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td></td>
<td>CRITICAL</td>
</tr>
<tr>
<td>Study Design/s</td>
<td>Key findings</td>
<td>Grade level of evidence</td>
</tr>
<tr>
<td>4 CHANG (2014)</td>
<td>Pediatric - Mucolytics - no significant difference between groups (odds ratio (OR) 0.40, 95% confidence interval (CI) 0.10 to 1.62)</td>
<td>LOW</td>
</tr>
<tr>
<td></td>
<td>In the combined data (adult &amp; pedia) meta-analysis showed no significant difference between groups for the primary outcome of 'not cured or not improved' (OR 0.85, 95% CI 0.40 to 1.80)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Decreased length of stay, treatment failure, time to recovery</th>
<th>Importance:</th>
</tr>
</thead>
<tbody>
<tr>
<td># of studies included in MA or SR (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>11 (Brown et al., 2020)</td>
<td>SR/MA</td>
<td>There is no evidence that adjunctive zinc treatment improves recovery from pneumonia in children in LMICs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment failure -  For all pxs (OR 0.95 (95% CI 0.80 to 1.14)  For severe pneumonia (OR 0.93 (95% CI 0.75 to 1.14)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Time to recovery - HR 1.01 (95% CI 0.89 to 1.14)</td>
</tr>
<tr>
<td>7 (Das et al., 2018)</td>
<td>SR/MA</td>
<td>time to resolution of acute illness (hours) (mean difference (MD) -0.95, 95%(CI) -6.14 to 4.24; mortality rate (risk ratio (RR) 0.97, 95% CI 0.06 to 15.28; duration of hospitalisation (MD 0.49, 95% CI -8.41 to 9.4 time to resolution of fever (MD 1.66, 95% CI -2.44 to 5.76)</td>
</tr>
</tbody>
</table>
| 13 (Yang et al., 2021) | SR/MA | Time to resolution of pneumonia (hours)  
\[MD = -1.02; 95\% CI, -5.74 to 3.70; P = .67; I^2 = 12\%\]  
Duration of hospitalization (hours).  
\[MD = -1.40; 95\% CI, -9.53 to 6.73; P = .74; I^2 = 12\%\]  
Recovery rate of pneumonia.  
Recovery rate of pneumonia in the vitamin D group (RR = 1.28; 95\% CI, 0.94–1.74; I^2 = 13\%) compared with that in the placebo group, which was not statistically different (P = .12) |

**CONTEXT AND CONSIDERATIONS**

Vitamin A is a necessary substrate for preserving epithelial cell integrity and also plays a role in immune modulation. WHO recommends that all children diagnosed with measles, in communities where vitamin A deficiency is a recognized problem, vitamin A should be administered as follows: 100,000 IU by mouth for infants younger than 12 months of age and 200,000 IU for older children. The dose should be repeated in 24 hours and after 4 weeks in the presence of ophthalmologic signs of vitamin A deficiency such as night blindness, xerophthalmia or Bitot’s spots (grayish white deposits on the bulbar conjunctiva adjacent to the cornea).

Mucokinetic agents like short-acting bronchodilators (SABA) and secretolytic or mucolytic agents such as ambroxol, carbocisteine, acetylcysteine, and bromhexine are not suggested to be used as adjunctive treatment during the course of illness of non-severe pneumonia due to the limited studies and conflicting outcomes that were reported in these studies (Chang et al., 2014). Furthermore, this same study also mentioned that there is insufficient evidence to decide whether OTC medications for cough associated with acute pneumonia are beneficial.

Bronchodilators are drugs that relax the airway smooth muscles. Narrowing or obstruction of the bronchial airways which leads to wheezing may occur during an infection, an episode of allergy and/or hyperreactive airway disease. Hence, bronchodilators are considered in PCAP in the presence of wheezing.

Based on the WHO recommendations, zinc can be added to the management of pediatric community acquired pneumonia, however recent evidences show that zinc does not shorten the recovery time of childhood pneumonia.

As part of standard of care in the management of pediatric community-acquired pneumonia, hydration and oxygenation if indicated must be administered.
REFERENCES


Clinical Question 12
among infants and children aged 3 months to 3 years, what interventions are effective for the prevention of community-acquired pneumonia?

CYNTHIA CECILIA J. DE OCAMPO, M.D.
JAY RON O. PADUA, M.D.

Key Recommendations

1. The following strategies are recommended to prevent PCAP:
   1.1 Vaccination against *Streptococcus pneumoniae* (pneumococcus), *Haemophilus influenzae* type b (Hib), *Bordetella pertussis* (pertussis), *Rubeola* virus (measles) and *Influenza* virus (Strong recommendation; high-grade evidence).
   1.2 Breastfeeding (Strong recommendation; high-grade evidence).
   1.3 Avoidance of environmental tobacco smoke or indoor biomass fuel exposure (Strong recommendation; high-grade evidence).
   1.4 Zinc supplementation (Strong recommendation; moderate-grade evidence).

2. There is insufficient evidence to recommend Vitamin A, C or D supplementation for the prevention of PCAP. (Very low-grade evidence).

Summary of Evidence

<table>
<thead>
<tr>
<th>Outcome 1</th>
<th>Disease prevention and PCV</th>
<th>Importance: Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of studies (and list of authors)</td>
<td>Study Design/s</td>
<td>Key findings</td>
</tr>
<tr>
<td>(Zar et al., 2020)</td>
<td>CPG</td>
<td>In children aged 24-59 months, a reduction of 9% (95%CI: 5-14%, p-value &lt; 0.001) and of 24% (95%CI: 12-33%, p-value &lt; 0.001) in the hospitalization rates for clinically and radiologically confirmed pneumonia, respectively, after the introduction of the novel PCVs.</td>
</tr>
<tr>
<td>12 (Alicino et al., 2017)</td>
<td>Meta-analysis of Cohort and Case-control studies</td>
<td>In children aged &lt; 24mos, a reduction of 17% (95%CI: 11-22%, p-value &lt; 0.001), and of 31% (95%CI: 26-35%, p-value &lt; 0.001) in the hospitalization rates respectively for clinically and radiologically confirmed pneumonia, respectively, after the introduction of the novel PCVs.</td>
</tr>
<tr>
<td>Outcome 2</td>
<td>Disease prevention and breastfeeding</td>
<td>Importance: Critical</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td><strong>Number of studies (and list of authors)</strong></td>
<td><strong>Study Design/s</strong></td>
<td><strong>Key findings</strong></td>
</tr>
<tr>
<td>(Zar et al., 2020)</td>
<td>CPG</td>
<td>Breastfeeding has been shown to decrease the incidence of pneumonia in young children by up to 32% (Wright et al., 1998) Shorter duration of breastfeeding is associated with pneumonia mortality, particularly among infants 95% confidence interval (CI) 0.67 - 332.74) (Lamberti et al., 2013)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcome 3</th>
<th>Disease prevention and avoidance of tobacco smoke or indoor biomass fuel exposure</th>
<th>Importance: Important</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of studies (and list of authors)</strong></td>
<td><strong>Study Design/s</strong></td>
<td><strong>Key findings</strong></td>
</tr>
<tr>
<td>(Zar et al., 2020)</td>
<td>CPG</td>
<td>Reduction in tobacco smoke or indoor fuel exposure Active and passive exposure to tobacco should be strongly discouraged in women of child-bearing age, particularly among pregnant women, and more generally in the household. Exposure to fumes from indoor cooking fuels should be limited by opening windows and doors when cooking; the chimney should function well; the stove should be cleaned and maintained; and there should be safe child location practices while fires are burning in the house. The practice of carrying children on caregivers’ backs while cooking is an independent risk factor for pneumonia morbidity and mortality. Children should sleep in rooms separate from where food is cooked</td>
</tr>
</tbody>
</table>
### Outcome 4
**Disease prevention and zinc supplementation**

<table>
<thead>
<tr>
<th>Number of studies (and list of authors)</th>
<th>Study Design/s</th>
<th>Key findings</th>
<th>Grade level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 (ZS et al., 2016)</td>
<td>SR/MA RCTs</td>
<td>Analysis showed that zinc supplementation reduced the incidence of pneumonia by 13% (fixed-effect risk ratio (RR) 0.87; 95% confidence interval (CI) 0.81 to 0.94, six studies, low-quality evidence) and prevalence of pneumonia by 41% (random-effects RR 0.59; 95% CI 0.35 to 0.99, one study, n = 609, low-quality evidence). On subgroup analysis, zinc reduced the incidence of pneumonia defined by specific clinical criteria by 21% (i.e. confirmation by chest examination or chest radiograph) (fixed-effect RR 0.79; 95% CI 0.71 to 0.88, four studies, n = 3261), but had no effect on lower specificity pneumonia case definition (i.e. age-specific fast breathing with or without lower chest indrawing) (fixed-effect RR 0.95; 95% CI 0.86 to 1.06, four studies, n = 1932)</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

---

### Outcome 5
**Disease prevention and Vitamin C supplementation**

<table>
<thead>
<tr>
<th>Number of studies (and list of authors)</th>
<th>Study Design/s</th>
<th>Key findings</th>
<th>Grade level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 (Padhani et al., 2020)</td>
<td>SR/MA RCTs (5)</td>
<td>Due to the small number of included studies and very low quality of the existing evidence, we are uncertain of the effect of vitamin C supplementation for the prevention and treatment of pneumonia.</td>
<td>Very Low</td>
</tr>
<tr>
<td></td>
<td>Quasi-RCT (2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

### Outcome 6
**Disease prevention and Vitamin D supplementation**

<table>
<thead>
<tr>
<th>Number of studies (and list of authors)</th>
<th>Study Design/s</th>
<th>Key findings</th>
<th>Grade level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 (MY et al., 2016)</td>
<td>SR/MA RCTs</td>
<td>For pneumonia, episodes of 'radiologically confirmed' first or only episode of pneumonia were little different in the supplemented and un-supplemented group (Rate Ratio: 1.06, 95% confidence interval (CI) 0.89 to 1.26; two trials, 3134 participants, moderate quality evidence), and similarly for children with confirmed or unconfirmed pneumonia (RR 0.95, 95% CI 0.87 to 1.04; one trial, 3046 participants). In the single large trial from Afghanistan, the trial authors reported that vitamin D supplementation was associated with an increase in repeat episodes of pneumonia confirmed by chest radiograph (RR 1.69, 95% CI 1.28 to 2.21; one trial, 3046 participants), but not reflected in the outcome of confirmed or unconfirmed pneumonia (RR 1.06, 95% CI 1.00 to 1.13; one trial, 3046 participants).</td>
<td>Very Low</td>
</tr>
</tbody>
</table>
CONTEXT AND CONSIDERATIONS

Advances in the prevention of paediatric pneumonia have led to a reduction in the burden of disease and have lowered the case fatality risk and mortality over the past two decades. The following strategies can prevent community-acquired pneumonia in children:

**Vaccination**

Pneumonia can be prevented by immunizing against *Haemophilus influenzae* type b (Hib), pneumococcus, measles and pertussis (whooping cough) (WHO 2015). WHO also recommends the inclusion of PCVs in childhood immunization programs worldwide. The use of pneumococcal vaccine should be complementary to other disease prevention and control measures, such as appropriate case management, promotion of exclusive breastfeeding for the first 6 months of life and reducing known risk factors such as indoor air pollution and tobacco smoke. The 23-valent pneumococcal polysaccharide vaccine is not routinely recommended for immunocompetent children and is only given to children >2 years old, who are at risk of developing invasive pneumococcal disease, including those with chronic diseases, with primary and secondary immune deficiencies and with functional or anatomical asplenia.

**Breastfeeding**

Nutrition including breastfeeding for the first six months of life plays a major role by boosting immunity against causative organisms of pneumonia (WHO 2015). Breastfeeding has been shown to decrease the incidence of pneumonia in young children by up to 32%. Shorter duration of breastfeeding is associated with pneumonia mortality, particularly among infants < 5 month of age. Mortality among infants who are not breastfed compared with exclusively breastfed infants through 5 months of age is ~15-fold higher (relative risk (RR) 14.97; 95% confidence interval (CI) 0.67 - 332.74). (Zar, 2020)

**Avoidance of environmental tobacco smoke or indoor biomass fuel exposure**

Pneumonia remains the leading cause of childhood mortality outside the neonatal period, in low- and middle-income countries. Environmental tobacco smoke (ETS) exposure is strongly associated with an increased risk for pneumonia and of severe disease. ETS exposure often begins in utero with maternal smoking or exposure. Antenatal or early-life ETS exposure, from maternal, household, or community contacts, may impact on the susceptibility of the infant to develop respiratory disease and impair lung development. However, the effects of postnatal tobacco smoke exposure may also be substantial, leading to poorer respiratory health. (Vanker, 2017). ETS exposure is reported as an important risk factor for childhood LRTI in several studies. A systematic review found smoking by either parent (OR 1.22, 95% CI 1.10-1.35), both parents (OR 1.62, 95% CI 1.38-1.89), or a household member (OR 1.54, 95% CI 1.40-1.69) significantly increased the risk of LRTI (Vanker, 2017). Exposure to household air pollution almost doubles the risk for childhood pneumonia and is responsible for 45% of all pneumonia deaths in children less than 5 years old. (WHO, Household Air Pollution and Health, 22 September, 2021)
Zinc supplementation

Zinc plays an important role in cell regeneration, immunity and growth. Zinc deficiency decreases T-lymphocytes and T-helper, impairs macrophage function and reduced killer cells, and adversely impacts innate immunity affecting interferon (IFN) gamma production, interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α) (Lassi, 2016). A local study done by Goyena et al. assessed the adequacy of dietary zinc intake and the prevalence and associated factors of serum zinc deficiency among Filipino preschool-age children 6-71 months old. Data from the 8th National Nutrition Survey (NNS) conducted in 2013, involving 2,892 preschool-age children, were analyzed. Almost half (47.2%) of preschool-age children had inadequate zinc intake. The national prevalence of serum zinc deficiency was 17.9%, and it is highest among children 6-23 months old and those from rural, poorest, and food-insecure households relative to other subgroups (Goyena, 2021). Daily supplementation with 10mg of Zinc (as gluconate or sulfate) for at least 4 to 6 months can prevent pneumonia in children aged 2 to 59 months. Zinc supplementation in children increases levels of complement in the blood that modulate the function of T-lymphocytes, T-helper, macrophages and neutrophils and hence improves the ability to fight infection. Zinc supplementation improves circulating levels of T-lymphocytes and other macrophages that enhance ability to fight infection. (Lassi, 2016)

The Technical Working Group did not find robust evidence that supplementation with vitamin A, C or D can prevent pneumonia in children.
REFERENCES


A. Vanker, *et al.* The association between environmental tobacco smoke exposure and childhood respiratory disease: a review; *Expert Review of Respiratory Medicine, 11*(8), 661-673, 2017. DOI: 10.1080/17476348.2017.1338949


AREAS FOR FUTURE RESEARCH

The 2021 PAPP/PIDSP Joint Task Force on PCAP has identified several gaps in knowledge in the evaluation and management of pediatric community-acquired pneumonia. There is paucity of data in some of the clinical questions due to limited high quality studies, more particularly in the local setting. Objective outcome measures should be established to understand fully the difference in the clinical course between causative agents, across all pediatric age groups and socio-economic strata. Relevant outcomes to be considered include time to resolution of observed abnormalities in the clinical and ancillary parameters, development of pneumonia-associated complications, and mortality. Other outcomes that can be measured to assess the effectiveness of interventions include the requirement for hospitalization, length of hospital stay, readmission after hospital discharge, persistence of clinical and laboratory signs and symptoms, and costs of care. These outcomes should be measured, standardized and compared to guide clinicians in decision-making and ultimately improve patient care. We, therefore, recommend adequately powered, well-designed and well-conducted clinical trials in the following areas to provide more specific, evidence-based guidance in the future:

- Identification of clinical feature/s or oxygen saturation level to accurately predict PCAP
- Evaluation of the accuracy of scoring systems using clinical features and oxygen saturation level in predicting the likelihood of PCAP
- Standard triage criteria for selection of the initial site of care, whether ambulatory or in-hospital settings, and to identify patients at high or low risk of clinical deterioration, pneumonia-associated complications and mortality
- Epidemiology of PCAP caused by specific bacteria, viruses, atypical bacteria, and presence of co-infection, especially in areas with good vaccine coverage against *Streptococcus pneumoniae* and *Hemophilus influenzae* type b
- Use of less or non-invasive diagnostic tests using blood, induced sputum, or other respiratory tract secretions and lung tissues that will reliably/accurately document clinical disease caused by one or more pathogens
- Use of laboratory tests, such as acute-phase reactants like procalcitonin, that to aid in clinical diagnosis, severity classification and assessment of appropriate treatment response in PCAP.
- Clinical, laboratory and epidemiological risk factors for severe PCAP, respiratory failure and hospitalization in the local setting
- Best imaging techniques that provide will high-quality diagnostic information with minimal radiation exposure
- Development and validation of a standard criteria for interpretation of chest radiographs in the diagnosis of PCAP
- Evaluation of the role of point-of-care chest ultrasonography (POCUS) as a diagnostic aid for PCAP in local setting
- Strengthening of antimicrobial resistance surveillance and reporting in the local and national levels and disseminate these data to guide local and institutional policy-makers of antimicrobial stewardship programs.
- Information on the lowest effective antimicrobial dose and shortest optimal duration of therapy to decrease risk of toxicity and development of resistance
• Role of antimicrobial therapy for atypical bacterial pathogens in PCAP particularly children <5 years of age.
• Assessment of the value of combination antimicrobial therapy for severe pneumonia, especially the addition of a macrolide in the regimen
• Impact of viral testing on patient outcomes and antibiotic prescribing behavior to avoid inappropriate use of antibiotic therapy.
• Use of clinical, laboratory, and oximetry parameters that will reliably assess the outcome of interventions for non-severe and severe PCAP
• Cost-effectiveness analysis of each diagnostic and therapeutic intervention for PCAP
• Standard discharge criteria required for children who continue to need antibiotics administered intravenously, intramuscularly, or orally
• Role of parenteral outpatient therapy for severe pneumonia and use oral antibiotics for severe bacterial PCAP in hospitalized patients
• Outcome of switch therapy in the management of severe PCAP
• Role of vitamin C and D in the treatment and prevention of PCAP
• Assessment of the value of adjunctive treatment (such as oral folate, probiotics, virgin coconut oil, steam inhalation, and nebulization with saline solution) in the management of PCAP
• Identification of non-clinical factors including psychosocial or behavioral concerns, socioeconomic issues, likelihood of non-adherence to prescribed therapy, and other barriers to medical care
• Analysis of medical costs in the management of PCAP, including non-medical costs such as lost parental income and family stress
• Long-term outcomes of children who had one or more episodes of PCAP
APPENDICES

Appendix A. Imaging modalities for Pediatric Community-Acquired Pneumonia

1. Chest radiography remains the initial imaging modality of choice to follow-up patients with PCAP. Frequency of follow-up will depend on patient's clinical status.
2. Chest CT scan is the next imaging tool for the following conditions:
   2.1 CT scan with IV contrast is an appropriate imaging tool for pneumonia complicated by suspected bronchopleural fistula or by lung abscess seen on the radiograph.
   2.2 CT scan without IV contrast is appropriate for non-localized recurrent pneumonia seen on the radiograph.
   2.3 CT scan with IV contrast or CT angiography is appropriate for localized recurrent pneumonia seen on the radiograph.
3. Chest Ultrasound is usually appropriate in immunocompetent children with pneumonia complicated with moderate or large effusion seen on chest radiograph.
4. CXR remains the initial imaging modality of choice to follow-up patients with PCAP. Frequency of follow-up will depend on patient's clinical status.
5. CT scan is the next imaging tool for the following conditions:
   5.1 CT scan with IV contrast is an appropriate imaging tool for pneumonia complicated by suspected bronchopleural fistula or by lung abscess seen on the radiograph.
   5.2 CT scan without IV contrast is appropriate for non-localized recurrent pneumonia seen on the radiograph.
   5.3 CT scan with IV contrast or CT angiography is appropriate for localized recurrent pneumonia seen on the radiograph.
6. Ultrasound is usually appropriate in immunocompetent children with pneumonia complicated with moderate or large effusion seen on chest radiograph.
Appendix B. 2016 PCAP CPG Key Recommendations (attach the actual soft copy of the 2016 CPG as some items are missing here)

**CLINICAL QUESTION 1**
1. A patient presenting initially with cough and/or respiratory difficulty may be evaluated for possible presence of pneumonia.
   1.1. Pneumonia may be considered if any of the following positive predictors of radiographic pneumonia is present. At the Emergency Room as the site-of-care.
      1.1.1. Oxygen saturation less than or equal to 94% at room air in a patient aged 3 months to 5 years, and above 5 years old in the absence of any comorbid neurologic, musculoskeletal, or cardiac conditions that may potentially affect oxygenation.
      1.1.2. Tachypnea [age specific as defined by World Health Organization [WHO] in a patient aged 3 months to 5 years, and above 5 years old.
      1.1.3. Chest wall retractions in a patient aged 3 months to 5 years [Recommendation Grade B2], and above 5 years old.
      1.1.4. Fever, grunting, wheezing, decreased breath sounds, nasal flaring, cyanosis, crackles, or localized chest findings at any age.
      1.1.5. Consolidation as visualized in lung ultrasound. At the Out-Patient Clinic as the site-of-care.
      1.1.6. Oxygen saturation less than or equal to 94% at room air in the absence of any comorbid neurologic, musculoskeletal, or cardiac conditions that may potentially affect oxygenation; tachypnea; chest wall retractions; fever; decreased breath sounds; nasal flaring; cyanosis; crackles; or localized chest findings at any age.
   1.2. Pneumonia may not be considered if any of the following negative predictors of radiographic pneumonia is present. At the Emergency Room as the site-of-care.
      1.2.1. Oxygen saturation greater than 94% at room air in a patient aged 3 months to 5 years, and above 5 years old.
      1.2.2. Absence of fever, nasal flaring and chest wall retractions in a patient aged 3 months to 5 years, and above 5 years old.
      At the Out-Patient Clinic as the site-of-care.
      1.2.3. Oxygen saturation greater than 94% at room air, and absence of fever, nasal flaring, or chest wall retractions.

2. Chest x-ray may be requested to determine the presence of pneumonia in any of the following situations:
   2.1. Dehydration in a patient aged 3 months to 5 years.
   2.2. High index of clinical suspicion.

**CLINICAL QUESTION 2**
1. A patient may be classified as pCAP A, B, C or D within 48 hours after consultation based on the following Risk-classification for Pneumonia-related mortality [Recommendation Grade D].

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Parameters</td>
<td>Non-severe</td>
<td>Severe or Moderate Risk</td>
<td>Very Severe or High Risk</td>
<td></td>
</tr>
</tbody>
</table>

1. Respiratory signs
   1.1. Retraction none IC/SC Supraclavicular/ IC/ SC
   1.2. Head bobbing none present present
   1.3. Cyanosis none present present
   1.4. Grunting none none present
1.5. Apnea  
1.6. Tachypnea

<table>
<thead>
<tr>
<th></th>
<th>none</th>
<th>none</th>
<th>present</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.6.1 3 to 12 months</td>
<td>&gt;50/min to &lt;60/min</td>
<td>&gt;60/min to &lt;70/min</td>
<td>&gt;70/min</td>
</tr>
<tr>
<td>1.6.2 1 to 5 years</td>
<td>&gt;40/min to &lt;50/min</td>
<td>&gt;50/min</td>
<td>&gt;50/min</td>
</tr>
<tr>
<td>1.6.3 &gt;5 years</td>
<td>&gt;30/min to &lt;35/min</td>
<td>&gt;35/min</td>
<td>&gt;35/min</td>
</tr>
</tbody>
</table>

2. Central nervous system signs

<table>
<thead>
<tr>
<th></th>
<th>none</th>
<th>irritable</th>
<th>lethargic/stuporous/comatose</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1. Altered sensorium</td>
<td>none</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>2.2. Convulsion</td>
<td>none</td>
<td>present</td>
<td>present</td>
</tr>
</tbody>
</table>

3. Circulatory signs

<table>
<thead>
<tr>
<th></th>
<th>none</th>
<th>Capillary refill &gt;3s</th>
<th>shock</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1. Poor perfusion</td>
<td>none</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>3.2. Pallor</td>
<td>none</td>
<td>present</td>
<td>present</td>
</tr>
</tbody>
</table>

4. General considerations

<table>
<thead>
<tr>
<th></th>
<th>none</th>
<th>mild</th>
<th>moderate</th>
<th>severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1. Malnutrition</td>
<td>none</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>4.2. Inability to drink</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>4.3. Co-morbid conditions</td>
<td>none</td>
<td>present</td>
<td>present</td>
<td>present</td>
</tr>
</tbody>
</table>

Ancillary Parameters

<table>
<thead>
<tr>
<th></th>
<th>none</th>
<th>present</th>
<th>present</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Chest x-ray findings of effusion, abscess, air leak or multi-lobar consolidation</td>
<td>none</td>
<td>present</td>
<td>present</td>
</tr>
<tr>
<td>6. Oxygen saturation at RA using pulse oximetry</td>
<td>&gt;95%</td>
<td>91% to 94%</td>
<td>&lt;90%</td>
</tr>
</tbody>
</table>

1. In order to classify to a higher risk category, at least 2 parameters [clinical and/or ancillary] may be present. In the absence of an ancillary parameter, clinical parameters may suffice.

2. Risk factors for mortality based on evidence and/or expert opinion among members of the 2016 PAPP Task Force on pCAP.

3. World Health Organization age-specific criteria for tachypnea for children under 5 years old.


5. Chest x-ray and pulse oximetry are desirable variables but not necessary as determinants of admission at site-of-care.

2. A patient initially classified as pCAP A or B but is not responding to current treatment after 48 hours may be admitted [Recommendation Grade D].

3. A patient classified as pCAP C may be:

   3.1. admitted to the regular ward [Recommendation Grade D].

   3.2. managed initially on an outpatient basis [Recommendation Grade D] if all of the following are not present at initial site-of-care [Recommendation Grade D].
       3.2.1. Age less than 2 years old
       3.2.2. Convulsion
       3.2.3. Chest x-ray with effusion, lung abscess, air leak or multi-lobar consolidation
       3.2.4. Oxygen saturation <95% at room air

4. A patient classified as pCAP D may be admitted to a critical care unit [Recommendation Grade D].

**CLINICAL QUESTION 3**

1. The following may be requested at initial site-of-care

   1.1. Clinically important endpoint: assessment of gas exchange
       1.1.1. Oxygen saturation using pulse oximetry.

   1.2. Clinically important endpoint: microbial determination of underlying etiology
       1.2.1. Gram stain and/or aerobic culture and sensitivity of sputum
1.3. Clinically important endpoint: clinical suspicion of necrotizing pneumonia, multilobar consolidation, lung abscess, pleural effusion, pneumothorax or pneumomediastinum
   1.3.1. Chest x-ray PA-lateral
   1.3.2. Chest ultrasound

2. The following may not be requested.
   2.1. Clinically important endpoint: microbial determination of underlying etiology
       2.1.1. Blood culture and sensitivity
   2.2. Clinically important endpoint: basis for initiating antibiotic treatment
       2.2.1. White blood cell [WBC] count
       2.2.2. C-reactive protein [CRP]
       2.2.3. Procalcitonin [PCT]

CLINICAL QUESTION 4
1. For PCAP C and PCAP D, the following diagnostic aids may be requested at initial site-of-care.
   Clinically important endpoint: assessment of gas exchange
   1.1. Oxygen saturation using pulse oximetry
   1.2. Arterial blood gas
   2. Clinically important endpoint: Surrogate markers for possible presence of pathogens requiring initial empiric antibiotic with microbiology as the reference standard
       2.1. C-reactive protein [CRP]
       2.2. Procalcitonin [PCT]
       2.3. Chest x-ray PA-lateral
       2.4. White blood cell [WBC]
   3. Clinically important endpoint: clinical suspicion of necrotizing pneumonia, multilobar consolidation, lung abscess, pleural effusion, pneumothorax or pneumomediastinum.
       3.1. Chest x-ray PA-lateral
       3.2. Chest ultrasound
   4. Clinically important endpoint: determination of underlying microbial etiology
       4.1. Gram stain and/or aerobic culture and sensitivity of sputum, nasopharyngeal aspirate and/or pleural fluid, and/or blood for PCAP C with lung abscess, empyema or pneumothorax
       4.2. Gram stain and/or aerobic culture and sensitivity of sputum, tracheal aspirate and/or pleural fluid, for PCAP D
       4.3. Anaerobic culture and sensitivity of sputum, nasopharyngeal aspirate, pleural fluid, and/or blood culture and sensitivity for
           4.3.1. PCAP C with lung abscess, empyema or pneumothorax
           4.3.2. PCAP D
       4.4. Serum IgM for Mycoplasma pneumoniae
   5. Clinically important endpoint: determination of metabolic derangement for immediate correction on admission
       5.1. pH in arterial blood gas for metabolic acidosis
       5.2. Serum sodium for hyponatremia
       5.3. Serum potassium for hypokalemia
   6. Clinically important endpoint: predictor of clinical outcome
       6.1. Predictive marker for mortality
           6.1.1. pH in arterial blood gas for metabolic acidosis
       6.2. Predictive marker for initial treatment failure
           6.2.1. Pulse oximetry for oxygen saturation less than 90% at room air, chest x-ray PA-lateral for pleural effusion or consolidation, or WBC for leukocytosis or leukopenia
           6.2.2. Blood culture for bacteremia, serum hemoglobin for anemia, or serum glucose for hypoglycemia
       6.3. Predictive marker for prolonged hospitalization or pneumatocele formation
           6.3.1. Lung ultrasound showing impaired perfusion and hypoechoic lesions
   7. For PCAP D, a referral to a specialist may be done for additional diagnostic tests
   8. For uncomplicated PCAP C, the following may not be requested.
8.1. Clinically important endpoint: determination of underlying microbial etiology
8.1.1. Blood culture

8.2. Clinically important endpoint: prediction of clinical outcome
8.2.1. CRP as marker for risk of treatment failure or prolonged hospitalization

CLINICAL QUESTION 5
1. For PCAP C, empiric antibiotics may be started if any of the following is present.
   1.1 Elevated serum C-reactive protein [CRP]
   1.2 Elevated serum procalcitonin level [PCT]
   1.3 Elevated white blood cell [WBC] count greater than 15,000
   1.4 Elevated lipocalin 2 [Lpc-2]
   1.5 Alveolar consolidation on chest x-ray
   1.6 Persistent high-grade fever without wheeze
2. For PCAP D, a specialist may be consulted

CLINICAL QUESTION 6
1. For a patient who has been classified as PCAP A or PCAP B without previous antibiotic, regardless of the immunization status against *Haemophilus Influenzae type b* or *Streptococcus pneumoniae*,
   1.1 Amoxicillin trihydrate may be given
      1.1.1. It may be given at 40-50 mg/kg/day, maximum dose of 1500 mg/day in 3 divided doses in areas with proven low antibiotic resistance to amoxicillin
      1.1.2. It may be given at 90 mg/kg/day in areas with proven high amoxicillin resistance
      1.1.3. It may be given for a minimum of 3 days.
      1.1.4. It may be given in 2 divided doses for a minimum of 5.
   1.2 Azithromycin [10 mg/kg/day OD for 3 days, or 10 mg/kg/day at day 1 then 5 mg/kg/day for day 2 to 5, maximum dose of 500 mg/day], or clarithromycin [15 mg/kg/day, maximum dose of 1000 mg/day in divided doses for 7 days] may be given if there is
      1.2.1. Known hypersensitivity to amoxicillin
      1.2.2. Suspicion of atypical organisms particularly *Mycoplasma pneumoniae*
2. For a patient who has been classified as PCAP C without previous antibiotic and
   2.1 Requiring hospitalization, and
      2.1.1. Has completed the primary immunization against *Haemophilus influenzae type b*, penicillin G [100,000 units/kg/day in 4 divided doses] may be given
      *Grading of recommendation in the 2012 PAPP 2nd Update in the Evaluation and Management of Pediatric Community-acquired Pneumonia was based on Sacket DL, Straus SE: Evidence Based Medicine 2000.
      **Please see methodology for description of grading of recommendation.*
      2.1.2. Has not completed the primary immunization, or immunization status unknown, against *Haemophilus influenzae type b*, ampicillin [100 mg/kg/day in 4 divided doses] may be given
      2.2. Who can tolerate oral feeding and does not require oxygen support, amoxicillin [40-50 mg/kg/day in areas of proven low amoxicillin resistance and 90 mg/kg/day maximum dose of 1500 mg/day in 3 divided doses for at most 7 days in areas of proven high amoxicillin resistance] may be given on an outpatient basis
3. For a patient who has been classified as PCAP D, a specialist may be consulted.
4. For a patient suspected to have community-acquired methicillin-resistant *Staphylococcus aureus*,
   4.1 Vancomycin may be started
   4.2 A specialist may be consulted
5. Ancillary treatment as provided in Clinical Question 11 may be given
CLINICAL QUESTION 7
1. For PCAP A, B, C or D in which a non-influenza virus is the suspected pathogen, antiviral drug therapy may not be beneficial.
2. For PCAP C or D, antiviral drug therapy for clinically suspected or laboratory-confirmed influenza virus to reduce
   2.1. risk of pneumonia may not be beneficial.
   2.2. time to symptom resolution may be beneficial.
   2.2.1. oseltamivir [for infants 3-8 months old at 3 mg/kg per dose twice daily x 5 days, for infants 9-11 months old at 3.5 mg/kg per dose twice daily x 5 days, for >12 months old: body weight 15-23 kg at 45 mg twice daily x 5 days, >23-40 kg at 60 mg twice daily x 5 days, >40 kg at 75 mg twice daily x 5 days; doses to be started within 48 hours of onset of influenza-like symptoms.
   2.2.2. zanamivir [for children >7 years old at 10 mg (two 5-mg inhalations) twice daily x 5 days, within 36 hours of onset of influenza-like symptoms.
3. Oseltamivir or zanamivir may be beneficial to reduce the burden of pneumonia during a flu epidemic.
4. Symptomatic and ancillary treatment may be beneficial.

CLINICAL QUESTION 8
1. Good clinical response to current therapeutic management may be assessed based on achieving clinical stability that is sustained for the immediate past 24 hours
   1.1. For PCAP A or B, clinical stability may be assessed within 24-48 hours after consultation if cough has improved or body temperature in Celsius has returned to normal
   1.2. For PCAP C, clinical stability may be assessed within 24-48 hours after admission if any of the following physiologic parameters has significantly improved or returned to normal
      1.2.1. Respiratory rate at full minute based on the WHO-defined, age-specific values for tachypnea
      1.2.2. Oxygen saturation at room air using pulse oximetry
      1.2.3. Body temperature in Celsius
      1.2.4. Cardiac rate at full minute based on Pediatric Advanced Life Support age-based values
      1.2.5. Work of breathing
   1.3. For PCAP D, clinical stability may be assessed within 48-72 hours after admission if all of the following physiologic parameters have significantly improved: respiratory rate at full minute based on the WHO-defined, age-specific values for tachypnea, oxygen saturation using pulse oximetry, body temperature in Celsius, cardiac rate at full minute based on Pediatric Advanced Life Support age-based values, and work of breathing
2. Good clinical response to current therapeutic management may not require chest x-ray or complete blood count to document treatment success at end of treatment

CLINICAL QUESTION 9
1. If a patient classified as either PCAP A or PCAP B is not improving, or clinically worsening, within 72 hours after initiating a therapeutic intervention [treatment failure], diagnostic evaluation to determine if any of the following is present may be considered
   1.1. Coexisting or other etiologic agents
   1.2. Etiologic agent resistant to current antibiotic, if being given
   1.3. Other diagnosis
      1.3.1. Pneumonia-related complication
         1.3.1.1. Necrotizing pneumonia
         1.3.1.2. Pleural effusion
      1.3.2. Asthma
      1.3.3. Pulmonary tuberculosis
2. If a patient below 5 years of age, and 5 years old or more classified as PCAP C is not improving, or clinically worsening, within 48 hours after initiating a therapeutic intervention [treatment failure], diagnostic evaluation to determine if any of the following is present may be considered.

2.1. Coexisting or other etiologic agents
2.2. Etiologic agent resistant to current antibiotic, if being given
2.3. Other diagnosis
   2.3.1. Pneumonia-related complication
      2.3.1.1. Acute respiratory failure
      2.3.1.2. Pleural effusion
      2.3.1.3. Pneumothorax
      2.3.1.4. Necrotizing pneumonia
      2.3.1.5. Lung abscess
   2.3.2. Asthma
   2.3.3. Pulmonary tuberculosis
   2.3.4. Sepsis

3. If a patient classified as PCAP D is clinically worsening within 24 hours after initiating a therapeutic intervention, referral to a specialist may be done.

CLINICAL QUESTION 10
1. For PCAP C, switch from intravenous antibiotic administration to oral form may be beneficial to reduce length of hospital stay provided all of the following are present.
   1.1. Current parenteral antibiotic has been given for at least 24 hours
   1.2. At least afebrile within the last 8 hours without current antipyretic drug
   1.3. Responsive to current antibiotic therapy as defined in Clinical Question 8
   1.4. Able to feed, and without vomiting or diarrhoea
   1.5. Without any current pulmonary [effusion / empyema, abscess, air leak, lobar consolidation or necrotizing pneumonia] or extrapulmonary [meningitis or sepsis] complications
   1.6. Oxygen saturation > 95% at room air

2. For PCAP D, referral to a specialist may be done if switch therapy is considered.

CLINICAL QUESTION 11
1. During the course of illness for PCAP A or PCAP B, the following 1.1. may be beneficial.
   1.1.1. Oral steroid in a patient with coexisting asthma.
   1.1.2. Bronchodilator in the presence of wheezing.
   1.2. may not be beneficial.
   1.2.1. Cough preparation or parenteral steroid in a patient without asthma.
   1.2.2. Elemental zinc, vitamin D3 and probiotic.

2. During the course of illness for PCAP C, the following
   2.1. may be beneficial.
      2.1.1. Use of either nasal catheter or nasal prong in administering oxygen.
      2.1.2. Zinc supplement in reducing mortality
      2.1.3. Use of bubble CPAP instead of low flow oxygen in improving oxygenation.
      2.1.4. Steroid or spirulina in reducing length of stay.
      2.1.5. Oxygen for oxygen saturation below 95% at room air in improving oxygenation.
   2.2. may not be beneficial.
      2.2.1. Zinc supplement in reducing treatment failure or length of hospital stay.
      2.2.2. Vitamin D3 in reducing length of hospital stay.
      2.2.3. Parenteral steroid, probiotic, virgin coconut oil, oral folate and nebulization using saline or acetylcysteine.

3. During the course of illness for PCAP D, referral to a specialist may be beneficial.
CLINICAL QUESTION 12
1. The following are beneficial in reducing the burden of hospitalization because of pneumonia:
   1.1. Conjugated vaccine (PCV 10 or 13) against *Streptococcus pneumoniae* (Grade A1)
   1.2. Vaccine against Hib (Grade C1), Influenza sp. (Grade C2), and Diphtheria, Pertussis, Rubeola, and Varicella (Grade D)
   1.3. Breastfeeding (Grade B1)
   1.4. Avoidance of cigarette smoke (Grade B1) and biomass fuel (Grade C1)
2. The following are not beneficial in reducing the impact of pneumonia:
   2.1. Zinc supplement (Grade A1)
   2.2. Vitamin D (Grade A2)